0001569329 Youngevity International, Inc. false --12-31 Q3 2020 0.001 0.001 5,000,000 5,000,000 8 8 161,135 161,135 161,135 161,135 5 5 0 0 129,332 129,332 9.75 9.75 590,273 590,273 578,898 578,898 14,877 0.001 0.001 50,000,000 50,000,000 32,236,994 32,236,994 30,274,601 30,274,601 0 469 500,000 7,871,000 4,700,000 5 25 75 3 76,924 116,655 3 0 0 0 7,871,000 1,649,000 5,000,000 4 4 4 2 2,000,000 5 6.00 6.00 8.00 8.00 5 3 3 5 150,000 3 4 631,579 4 4 161,135 0.1 6,098 4 386,000 3 876,000 4.88 3 7,871,000 16 2 Interest on lease liabilities are classified within interest expense, net. Amortization of leased assets are classified as a component of depreciation and amortization. Assets held for sale at September 30, 2020 consisted of approximately $1,053,000 in land and $443,000 in computer equipment related to the commercial hemp segment. (See Note 13) Finance lease right-of-use assets are recorded within property and equipment, net of accumulated amortization of approximately $926,000 and $788,000 at September 30, 2020 and December 31, 2019, respectively. Operating lease costs are classified within selling and marketing and general and administrative expenses. 00015693292020-01-012020-09-30 xbrli:shares 00015693292022-06-17 thunderdome:item iso4217:USD 00015693292020-09-30 00015693292019-12-31 0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2020-09-30 0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2019-12-31 iso4217:USDxbrli:shares xbrli:pure 0001569329ygyi:SeriesAConvertiblePreferredStockMember2020-01-012020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMember2019-01-012019-12-31 0001569329ygyi:SeriesAConvertiblePreferredStockMember2020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMember2019-12-31 0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-01-012020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-01-012019-12-31 0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-01-012019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-12-31 00015693292020-07-012020-09-30 00015693292019-07-012019-09-30 00015693292019-01-012019-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-06-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-06-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-06-30 0001569329us-gaap:CommonStockMember2020-06-30 0001569329us-gaap:AdditionalPaidInCapitalMember2020-06-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0001569329us-gaap:RetainedEarningsMember2020-06-30 00015693292020-06-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:CommonStockMember2020-07-012020-09-30 0001569329us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-30 0001569329us-gaap:RetainedEarningsMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:CommonStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-07-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2020-07-012020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-09-30 0001569329us-gaap:CommonStockMember2020-09-30 0001569329us-gaap:AdditionalPaidInCapitalMember2020-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-30 0001569329us-gaap:RetainedEarningsMember2020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-12-31 0001569329us-gaap:CommonStockMember2019-12-31 0001569329us-gaap:AdditionalPaidInCapitalMember2019-12-31 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0001569329us-gaap:RetainedEarningsMember2019-12-31 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:CommonStockMember2020-01-012020-09-30 0001569329us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-30 0001569329us-gaap:RetainedEarningsMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:CommonStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-09-30 0001569329us-gaap:ShareBasedPaymentArrangementNonemployeeMemberus-gaap:CommonStockMember2020-01-012020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329us-gaap:CommonStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329us-gaap:RetainedEarningsMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329ygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329us-gaap:CommonStockMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329us-gaap:RetainedEarningsMemberygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329ygyi:SharesWithHempJointVentureAgreementMember2020-01-012020-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-06-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-06-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-06-30 0001569329us-gaap:CommonStockMember2019-06-30 0001569329us-gaap:AdditionalPaidInCapitalMember2019-06-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-30 0001569329us-gaap:RetainedEarningsMember2019-06-30 00015693292019-06-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329us-gaap:CommonStockMember2019-07-012019-09-30 0001569329us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-30 0001569329us-gaap:RetainedEarningsMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:CommonStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:RetainedEarningsMember2019-07-012019-09-30 0001569329ygyi:WarrantsForServiceMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:CommonStockMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:RetainedEarningsMember2019-07-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMember2019-07-012019-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-09-30 0001569329us-gaap:CommonStockMember2019-09-30 0001569329us-gaap:AdditionalPaidInCapitalMember2019-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-30 0001569329us-gaap:RetainedEarningsMember2019-09-30 00015693292019-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-31 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2018-12-31 0001569329us-gaap:CommonStockMember2018-12-31 0001569329us-gaap:AdditionalPaidInCapitalMember2018-12-31 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31 0001569329us-gaap:RetainedEarningsMember2018-12-31 00015693292018-12-31 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:CommonStockMember2019-01-012019-09-30 0001569329us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-30 0001569329us-gaap:RetainedEarningsMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:CommonStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMemberus-gaap:RetainedEarningsMember2019-01-012019-09-30 0001569329ygyi:WarrantsForServiceMember2019-01-012019-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329us-gaap:CommonStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329us-gaap:RetainedEarningsMemberygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329ygyi:UnderwrittenRegisteredPublicOfferingMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:CommonStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMemberus-gaap:RetainedEarningsMember2019-01-012019-09-30 0001569329ygyi:WarrantsUponVestingForServiceMember2019-01-012019-09-30 0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329us-gaap:PrivatePlacementMember2019-01-012019-09-30 0001569329us-gaap:LandMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:LandMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:LandMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:LandMemberus-gaap:CommonStockMember2019-01-012019-09-30 0001569329us-gaap:LandMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-30 0001569329us-gaap:LandMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-30 0001569329us-gaap:LandMemberus-gaap:RetainedEarningsMember2019-01-012019-09-30 0001569329us-gaap:LandMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberus-gaap:CommonStockMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMemberus-gaap:RetainedEarningsMember2019-01-012019-09-30 0001569329us-gaap:TrademarksMember2019-01-012019-09-30 0001569329ygyi:PromissoryNotesMember2020-01-012020-09-30 0001569329ygyi:PromissoryNotesMember2019-01-012019-09-30 0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2020-01-012020-09-30 0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2019-01-012019-09-30 0001569329us-gaap:ConvertibleNotesPayableMember2020-01-012020-09-30 0001569329us-gaap:ConvertibleNotesPayableMember2019-01-012019-09-30 0001569329ygyi:PropertyAndEquipmentFundedByFinancingLeasingAgreementMember2020-01-012020-09-30 0001569329ygyi:PropertyAndEquipmentFundedByFinancingLeasingAgreementMember2019-01-012019-09-30 0001569329ygyi:PropertyAndEquipmentFundedByMortgageAgreementMember2020-01-012020-09-30 0001569329ygyi:PropertyAndEquipmentFundedByMortgageAgreementMember2019-01-012019-09-30 0001569329ygyi:StockForNicaHempProjectMember2020-01-012020-09-30 0001569329ygyi:StockForNicaHempProjectMember2019-01-012019-09-30 0001569329ygyi:StockIssuedForPromissoryNoteFinancingMember2020-01-012020-09-30 0001569329ygyi:StockIssuedForPromissoryNoteFinancingMember2019-01-012019-09-30 0001569329ygyi:StockInConnectionWithAcquisitionMember2020-01-012020-09-30 0001569329ygyi:StockInConnectionWithAcquisitionMember2019-01-012019-09-30 0001569329ygyi:StockIssuedForServiceMember2020-01-012020-09-30 0001569329ygyi:StockIssuedForServiceMember2019-01-012019-09-30 0001569329ygyi:StockForPropertyAndEquipmentMember2020-01-012020-09-30 0001569329ygyi:StockForPropertyAndEquipmentMember2019-01-012019-09-30 0001569329ygyi:StockForPurchaseOfIntangiblesMember2020-01-012020-09-30 0001569329ygyi:StockForPurchaseOfIntangiblesMember2019-01-012019-09-30 0001569329ygyi:StockForNoteReceivablesMember2020-01-012020-09-30 0001569329ygyi:StockForNoteReceivablesMember2019-01-012019-09-30 0001569329ygyi:DirectSellingSegmentMember2020-07-012020-09-30 0001569329ygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329ygyi:CommercialHempSegmentMember2020-07-012020-09-30 0001569329ygyi:DirectSellingSegmentMember2019-07-012019-09-30 0001569329ygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329ygyi:CommercialHempSegmentMember2019-07-012019-09-30 0001569329ygyi:DirectSellingSegmentMember2020-01-012020-09-30 0001569329ygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329ygyi:CommercialHempSegmentMember2020-01-012020-09-30 0001569329ygyi:DirectSellingSegmentMember2019-01-012019-09-30 0001569329ygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329ygyi:CommercialHempSegmentMember2019-01-012019-09-30 utr:acre 0001569329ygyi:CoffeePlantationMember2020-09-30 0001569329ygyi:DryprocessingFacilityMember2020-09-30 0001569329us-gaap:WarrantMember2020-01-012020-09-30 0001569329us-gaap:WarrantMember2019-01-012019-09-30 0001569329ygyi:PreferredStockConversionsMember2020-01-012020-09-30 0001569329ygyi:PreferredStockConversionsMember2019-01-012019-09-30 0001569329ygyi:PrincipalConversionOnConvertibleNotesMember2020-01-012020-09-30 0001569329ygyi:PrincipalConversionOnConvertibleNotesMember2019-01-012019-09-30 0001569329us-gaap:EmployeeStockOptionMember2020-01-012020-09-30 0001569329us-gaap:EmployeeStockOptionMember2019-01-012019-09-30 0001569329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-30 0001569329us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-30 0001569329ygyi:BeneyouMembersrt:MaximumMember2019-11-012019-11-01 0001569329ygyi:BeneyouMember2019-11-012019-11-01 0001569329ygyi:BeneyouMember2019-11-01 0001569329ygyi:BeneyouMemberus-gaap:TrademarksAndTradeNamesMember2019-11-01 0001569329ygyi:BeneyouMemberygyi:DistributorOrganizationMember2019-11-01 0001569329ygyi:BeneyouMemberus-gaap:CustomerRelationshipsMember2019-11-01 0001569329ygyi:BeneyouMemberus-gaap:NoncompeteAgreementsMember2019-11-01 utr:Y 0001569329ygyi:BeneyouMemberus-gaap:TrademarksAndTradeNamesMember2019-11-012019-11-01 0001569329ygyi:BeneyouMemberygyi:DistributorOrganizationMember2019-11-012019-11-01 0001569329ygyi:BeneyouMemberus-gaap:CustomerRelationshipsMember2019-11-012019-11-01 0001569329ygyi:BeneyouMemberus-gaap:NoncompeteAgreementsMember2019-11-012019-11-01 0001569329ygyi:AepaWithKhrysosGlobalMember2019-02-122019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:CommonStockMember2019-02-122019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-02-122019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-02-132019-12-31 0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-12-312019-12-31 0001569329ygyi:AccruedExpensesMemberygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2020-09-30 0001569329ygyi:AccruedExpensesMemberygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-12-31 0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ContingentConsiderationPayableInCashMember2019-02-122019-02-12 0001569329ygyi:KhrysosGlobalMember2019-02-12 0001569329ygyi:KhrysosGlobalMemberus-gaap:TrademarksAndTradeNamesMember2019-02-12 0001569329ygyi:KhrysosGlobalMemberus-gaap:CustomerRelationshipsMember2019-02-12 0001569329ygyi:KhrysosGlobalMemberus-gaap:NoncompeteAgreementsMember2019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMember2019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:TrademarksAndTradeNamesMember2019-02-122019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:CustomerRelationshipsMember2019-02-122019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:NoncompeteAgreementsMember2019-02-122019-02-12 0001569329ygyi:AepaWithKhrysosGlobalMember2019-12-31 0001569329ygyi:CLRMemberygyi:HhMember2020-07-012020-09-30 0001569329ygyi:CLRMemberygyi:HhMember2020-01-012020-09-30 0001569329ygyi:CLRMemberygyi:HhExportMember2020-07-012020-09-30 0001569329ygyi:CLRMemberygyi:HhExportMember2020-01-012020-09-30 0001569329ygyi:CLRMemberygyi:HhExportMember2019-01-012019-09-30 0001569329ygyi:CLRMemberygyi:HhExportMember2020-07-112020-09-30 0001569329ygyi:CLRMemberygyi:HhExportMember2019-07-012019-09-30 0001569329ygyi:CustomerRelatedRevenueReceivablesMemberygyi:CLRMemberygyi:HhExportMember2020-09-30 0001569329ygyi:CustomerRelatedRevenueReceivablesMemberygyi:CLRMemberygyi:HhExportMember2019-12-31 0001569329ygyi:CLRMemberygyi:HhExportMember2019-01-012019-12-31 0001569329ygyi:CLRMemberygyi:GreenCoffeeAcquisitionMemberygyi:HhMember2020-09-30 0001569329ygyi:CLRMemberygyi:BillingForFreightAndOtherChargesMemberygyi:HhMember2020-09-30 0001569329ygyi:CLRMemberygyi:MillOperationCostMemberygyi:HhMember2020-09-30 0001569329ygyi:CLRMemberygyi:GreenCoffeeSoldButNotDeliveredMemberygyi:HhMember2020-09-30 0001569329ygyi:NicaraguanAgencyMemberygyi:HhExportGroupMember2020-03-31 0001569329ygyi:CLRMemberygyi:HhExportMember2020-03-31 iso4217:USDutr:lb 0001569329ygyi:CLRMemberygyi:HhExportMember2020-01-012020-03-31 0001569329ygyi:CLRMemberygyi:HhExportMember2018-12-31 0001569329ygyi:CLRMemberygyi:HhExportMember2019-03-31 0001569329ygyi:CLRMemberygyi:HhExportMember2019-03-012019-03-31 0001569329ygyi:CLRMemberygyi:HhExportMember2020-09-30 0001569329ygyi:CLRMemberygyi:HhExportMember2019-12-31 0001569329ygyi:CLRMemberygyi:MatagalpaPropertyMemberygyi:NicaraguanPartnerMember2019-01-31 0001569329ygyi:NicaraguanPartnerMember2019-01-31 0001569329ygyi:CLRMember2019-01-31 0001569329ygyi:HhExportMember2019-01-012019-01-31 0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2020-07-012020-09-30 0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2020-01-012020-09-30 0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012019-09-30 0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012020-09-30 0001569329ygyi:CLRMemberygyi:OperatingEquipmentMember2019-01-012020-09-30 0001569329ygyi:NicaraguanPartnerMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012020-09-30 0001569329ygyi:HhExportMember2020-01-012020-09-30 0001569329ygyi:HhExportMember2019-01-012019-12-31 0001569329ygyi:SharesWithHempJointVentureAgreementMember2020-07-012020-07-31 0001569329ygyi:WarrantsWithHempJointVentureAgreementMember2020-07-31 0001569329ygyi:NicaraguanJvPartnersMember2020-07-31 0001569329ygyi:UsPartnersMember2020-07-31 0001569329ygyi:CLRMemberygyi:HhExportMemberygyi:SharesIssuedForPurchaseConsiderationMember2019-01-012019-01-31 0001569329ygyi:CLRMemberygyi:HhExportMemberygyi:SharesIssuedForPurchaseConsiderationMember2019-01-31 0001569329ygyi:CLRMemberygyi:MrHernandezMember2017-05-31 0001569329ygyi:WvnpMember2020-01-012020-03-31 0001569329ygyi:WvnpMember2019-07-012019-09-30 0001569329ygyi:WvnpMember2019-01-012019-09-30 0001569329ygyi:DistributorCommissionMemberygyi:WvnpMember2020-01-012020-03-31 0001569329ygyi:CreditNoteMemberygyi:MrGroverMember2020-09-30 0001569329ygyi:CreditNoteMemberygyi:MrGroverMember2019-12-31 0001569329ygyi:WarrantsWith2014ConvertibleNoteMemberygyi:MrGroverMember2019-07-012019-07-31 0001569329ygyi:WarrantsWith2014ConvertibleNoteMemberygyi:MrGroverMember2019-07-31 0001569329ygyi:WarrantsWith2014ConvertibleNoteMemberygyi:MrGroverMembersrt:ScenarioForecastMember2020-12-31 0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-09-30 0001569329ygyi:WarrantsWith2014PrivatePlacementMemberygyi:PaulSallwasserMember2020-09-30 0001569329ygyi:ConversionOf2017ConvertiblePrivatePlacementNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-09-30 0001569329ygyi:WarrantsWith2017PrivatePlacementMemberygyi:PaulSallwasserMember2020-09-30 0001569329ygyi:ConversionOf2017ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-09-30 0001569329ygyi:WarrantsWith2017ConvertibleNoteMemberygyi:PaulSallwasserMember2020-09-30 0001569329ygyi:ConversionOf2017ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2018-03-012018-03-31 0001569329ygyi:WarrantsWith2017ConvertibleNoteMemberygyi:PaulSallwasserMember2018-03-31 0001569329ygyi:PaulSallwasserMember2019-08-012019-08-31 0001569329ygyi:PaulSallwasserMember2020-09-30 0001569329ygyi:PaulSallwasserMember2019-09-30 0001569329ygyi:MrDanielManglessMember2019-02-012019-02-28 0001569329ygyi:MrDanielManglessMember2019-02-28 0001569329ygyi:MrDanielManglessMember2019-06-012019-06-30 0001569329ygyi:MrDanielManglessMember2019-06-30 0001569329ygyi:MrDanielManglessMember2020-03-31 0001569329ygyi:MrDanielManglessMember2020-03-012020-03-31 0001569329ygyi:MrDanielManglessMembersrt:ScenarioForecastMember2021-04-012021-04-30 0001569329ygyi:JjeEquipmentMember2020-09-30 0001569329ygyi:JjeEquipmentMember2019-12-31 0001569329ygyi:YoungevityBeTheChangeFoundationMember2020-07-012020-09-30 0001569329ygyi:YoungevityBeTheChangeFoundationMember2019-07-012019-09-30 0001569329ygyi:YoungevityBeTheChangeFoundationMember2020-01-012020-09-30 0001569329ygyi:YoungevityBeTheChangeFoundationMember2019-01-012019-09-30 0001569329ygyi:CurrentLiabilitiesMemberygyi:YoungevityBeTheChangeFoundationMember2020-09-30 0001569329ygyi:CurrentLiabilitiesMemberygyi:YoungevityBeTheChangeFoundationMember2019-12-31 0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2014-09-30 0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2019-12-31 0001569329ygyi:PrivatePlacement2014Memberygyi:DouglasBriskieMember2014-08-31 0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329ygyi:CustomerDepositsMember2020-09-30 0001569329ygyi:CustomerDepositsMember2019-12-31 0001569329ygyi:RewardsProgramMember2020-09-30 0001569329ygyi:HeritageMakersMember2020-09-30 0001569329ygyi:HeritageMakersMember2019-12-31 0001569329ygyi:ConventionAndDistributorEventsMember2019-12-31 0001569329ygyi:ConventionAndDistributorEventsMember2020-09-30 0001569329ygyi:CommercialCoffeeSegmentMember2020-09-30 0001569329ygyi:CommercialCoffeeSegmentMember2019-12-31 0001569329ygyi:CommercialHempSegmentMember2020-09-30 0001569329ygyi:CommercialHempSegmentMember2019-12-31 0001569329ygyi:HhExportMember2019-12-31 0001569329ygyi:HhExportMember2020-01-012020-09-30 0001569329ygyi:HhExportMember2019-01-012019-12-31 0001569329us-gaap:BuildingMember2020-09-30 0001569329us-gaap:BuildingMember2019-12-31 0001569329us-gaap:LeaseholdImprovementsMember2020-09-30 0001569329us-gaap:LeaseholdImprovementsMember2019-12-31 0001569329us-gaap:LandMember2020-09-30 0001569329us-gaap:LandMember2019-12-31 0001569329us-gaap:LandImprovementsMember2020-09-30 0001569329us-gaap:LandImprovementsMember2019-12-31 0001569329ygyi:ProducingCoffeeTreesMember2020-09-30 0001569329ygyi:ProducingCoffeeTreesMember2019-12-31 0001569329ygyi:ManufacturingEquipmentMember2020-09-30 0001569329ygyi:ManufacturingEquipmentMember2019-12-31 0001569329ygyi:FurnitureAndOtherEquipmentMember2020-09-30 0001569329ygyi:FurnitureAndOtherEquipmentMember2019-12-31 0001569329ygyi:ComputerSoftwareMember2020-09-30 0001569329ygyi:ComputerSoftwareMember2019-12-31 0001569329us-gaap:ComputerEquipmentMember2020-09-30 0001569329us-gaap:ComputerEquipmentMember2019-12-31 0001569329us-gaap:VehiclesMember2020-09-30 0001569329us-gaap:VehiclesMember2019-12-31 0001569329ygyi:AssetsHeldForSaleMember2020-09-30 0001569329ygyi:AssetsHeldForSaleMember2019-12-31 0001569329us-gaap:ConstructionInProgressMember2020-09-30 0001569329us-gaap:ConstructionInProgressMember2019-12-31 0001569329us-gaap:LandMember2020-09-30 0001569329us-gaap:ComputerEquipmentMemberygyi:CommercialHempSegmentMember2020-09-30 0001569329ygyi:CbdOilExtractionEquipmentWithVfiMember2020-08-31 0001569329ygyi:CbdOilExtractionEquipmentWithVfiMember2020-08-012020-08-31 0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2020-07-012020-09-30 0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2019-07-012019-09-30 0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2020-01-012020-09-30 0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2019-01-012019-09-30 0001569329ygyi:DepreciationAndAmortizationMember2020-07-012020-09-30 0001569329ygyi:DepreciationAndAmortizationMember2019-07-012019-09-30 0001569329ygyi:DepreciationAndAmortizationMember2020-01-012020-09-30 0001569329ygyi:DepreciationAndAmortizationMember2019-01-012019-09-30 0001569329us-gaap:InterestExpenseMember2020-07-012020-09-30 0001569329us-gaap:InterestExpenseMember2019-07-012019-09-30 0001569329us-gaap:InterestExpenseMember2020-01-012020-09-30 0001569329us-gaap:InterestExpenseMember2019-01-012019-09-30 0001569329ygyi:DistributorOrganizationMember2020-09-30 0001569329ygyi:DistributorOrganizationMember2019-12-31 0001569329us-gaap:TrademarksAndTradeNamesMember2020-09-30 0001569329us-gaap:TrademarksAndTradeNamesMember2019-12-31 0001569329us-gaap:CustomerRelationshipsMember2020-09-30 0001569329us-gaap:CustomerRelationshipsMember2019-12-31 0001569329ygyi:InternallyDevelopedSoftwareMember2020-09-30 0001569329ygyi:InternallyDevelopedSoftwareMember2019-12-31 0001569329us-gaap:NoncompeteAgreementsMember2020-09-30 0001569329us-gaap:NoncompeteAgreementsMember2019-12-31 0001569329us-gaap:TrademarksMember2020-09-30 0001569329us-gaap:TrademarksMember2019-12-31 0001569329ygyi:DirectSellingSegmentMember2020-09-30 0001569329ygyi:DirectSellingSegmentMember2019-12-31 0001569329ygyi:CLRMemberygyi:CreditNoteMember2018-12-31 0001569329ygyi:CLRMemberygyi:CreditNoteMember2019-12-31 0001569329ygyi:CLRMemberygyi:CreditNoteMember2020-09-30 0001569329ygyi:WarrantWithCreditNotesOneMember2018-12-31 0001569329ygyi:WarrantsWithCreditNotesTwoMember2018-12-31 0001569329ygyi:CreditNoteMember2018-12-31 0001569329ygyi:CreditNotesWarrantsWithAdvisoryAgreementMember2018-12-31 0001569329ygyi:CreditNoteMember2020-07-012020-09-30 0001569329ygyi:CreditNoteMember2019-07-012019-09-30 0001569329ygyi:CreditNoteMember2020-01-012020-09-30 0001569329ygyi:CreditNoteMember2019-01-012019-09-30 0001569329ygyi:CreditNoteMember2020-09-30 0001569329ygyi:CreditNoteMember2019-12-31 0001569329ygyi:PromissoryNotes2019Member2019-03-012019-03-31 0001569329ygyi:PromissoryNotes2019Member2019-03-31 0001569329ygyi:PromissoryNotes2019Member2020-09-30 0001569329ygyi:PromissoryNotes2019Member2019-12-31 0001569329ygyi:SharesInConnectionWithPromissoryNotes2019Member2019-03-012019-03-31 0001569329ygyi:WarrantsInConnectionWithPromissoryNotes2019Member2019-03-31 0001569329ygyi:PromissoryNotes2019Member2020-07-012020-09-30 0001569329ygyi:PromissoryNotes2019Member2019-07-012019-09-30 0001569329ygyi:PromissoryNotes2019Member2020-01-012020-09-30 0001569329ygyi:PromissoryNotes2019Member2019-01-012019-09-30 0001569329ygyi:ManglessNoteMember2020-03-31 0001569329ygyi:StockInConnectionWithManglessNoteMember2020-03-012020-03-31 0001569329ygyi:ManglessNoteMember2020-07-012020-09-30 0001569329ygyi:ManglessNoteMember2020-01-012020-09-30 0001569329ygyi:ManglessNoteMember2020-09-30 0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWithManglessNoteMember2021-04-012021-04-30 0001569329ygyi:BoswellMortgageNote2400Member2013-12-31 0001569329ygyi:BoswellMortgageNote2400Member2013-01-012013-12-31 0001569329ygyi:BoswellMortgageNote2400Memberus-gaap:PrimeRateMember2013-01-012013-12-31 0001569329ygyi:BoswellMortgageNote2400Member2020-01-012020-09-30 0001569329ygyi:BoswellMortgageNote2400Member2019-01-012019-12-31 0001569329ygyi:BoswellMortgageNote2400Member2020-09-30 0001569329ygyi:BoswellMortgageNote2400Member2019-12-31 0001569329ygyi:KhrysosMortgageNotesForPropertiesInClemontFloridaMember2020-03-31 0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2020-03-31 0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2020-09-30 0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2019-12-31 0001569329ygyi:LandInGrovelandFloridaMember2019-02-28 0001569329ygyi:LandInGrovelandFloridaMember2019-02-012019-02-28 0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2019-02-28 0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2020-09-30 0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2019-12-31 0001569329ygyi:M2cPurchaseAgreementMember2007-03-012007-03-31 0001569329ygyi:M2cPurchaseAgreementMember2007-03-31 0001569329ygyi:M2cPurchaseAgreementMember2020-09-30 0001569329ygyi:M2cPurchaseAgreementMember2019-12-31 0001569329ygyi:CommercialCoffeeSegmentMember2020-07-012021-07-31 00015693292020-04-012020-04-30 0001569329ygyi:DirectSellingSegmentMember2020-04-012020-04-30 0001569329ygyi:CommercialCoffeeSegmentMember2020-04-012020-04-30 0001569329ygyi:CommercialHempSegmentMember2020-04-012020-04-30 0001569329ygyi:MortgageDebtMember2020-07-012020-09-30 0001569329ygyi:CommercialHempSegmentMembersrt:ScenarioForecastMember2020-11-012020-11-30 0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2021-04-012021-04-30 0001569329srt:ScenarioForecastMember2021-06-012021-06-30 0001569329ygyi:OtherNotesRelatedToLoansForCommercialVansMember2020-09-30 0001569329ygyi:OtherNotesRelatedToLoansForCommercialVansMember2019-12-31 0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2020-09-30 0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMembersrt:ScenarioForecastMember2022-01-31 0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMemberus-gaap:PrimeRateMember2020-01-012020-09-30 0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2020-01-012020-09-30 0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2019-12-31 0001569329ygyi:PipeNotes2019Member2020-09-30 0001569329ygyi:PipeNotes2019Member2019-12-31 0001569329ygyi:PipeNotes2014Member2020-09-30 0001569329ygyi:PipeNotes2014Member2019-12-31 0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-07-31 0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-07-31 0001569329ygyi:SubscriptionAgreementMember2019-07-31 0001569329ygyi:PipeNotes2019Member2019-07-31 0001569329ygyi:PipeNotes2019ConvertedIntoCommonStockMember2019-07-31 0001569329ygyi:PipeNotes2019Member2020-01-012020-09-30 0001569329ygyi:PipeNotes2019Member2019-01-012019-09-30 0001569329ygyi:PipeNotes2019AmendmentMembersrt:ScenarioForecastMember2021-03-31 0001569329ygyi:PipeNotes2014Member2014-07-012014-09-30 0001569329ygyi:PipeNotes2014Member2014-09-30 0001569329ygyi:Pipe2014DebtConvertedIntoCommonStockMember2014-07-012014-09-30 0001569329ygyi:Pipe2014DebtConvertedIntoCommonStockMember2014-09-30 0001569329ygyi:WarrantsWith2014PrivatePlacementMember2014-09-30 0001569329ygyi:PipeNotes2014Member2019-09-30 0001569329ygyi:PipeNotes2014Member2019-01-012019-09-30 0001569329ygyi:WarrantsMember2019-12-31 0001569329ygyi:WarrantsMember2020-09-30 0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2019-12-31 0001569329us-gaap:FairValueInputsLevel1Member2020-09-30 0001569329us-gaap:FairValueInputsLevel2Member2020-09-30 0001569329us-gaap:FairValueInputsLevel3Member2020-09-30 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel1Member2020-09-30 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel2Member2020-09-30 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-09-30 0001569329us-gaap:FairValueInputsLevel1Member2019-12-31 0001569329us-gaap:FairValueInputsLevel2Member2019-12-31 0001569329us-gaap:FairValueInputsLevel3Member2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel1Member2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel2Member2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2019-12-31 0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-30 0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2019-12-31 0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2020-01-012020-09-30 0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2020-09-30 0001569329us-gaap:MeasurementInputDiscountRateMember2020-09-30 0001569329us-gaap:MeasurementInputDiscountRateMember2019-12-31 0001569329us-gaap:SeriesCPreferredStockMember2020-09-30 00015693292018-05-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2018-05-012020-09-30 0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-31 0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-012020-03-31 0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-31 0001569329ygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2020-03-012020-03-31 0001569329ygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2020-03-012020-03-31 0001569329srt:ScenarioForecastMemberygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2021-04-012021-04-30 0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-06-012019-06-30 0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-06-30 0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-02-012019-02-28 0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-02-28 0001569329ygyi:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember2019-02-28 0001569329ygyi:PurchaseAgreementSharesIssuedForConsultingFeesMember2019-02-012019-02-28 0001569329ygyi:PurchaseAgreementSharesIssuedForConsultingFeesMember2019-02-28 0001569329ygyi:PurchaseAgreementsWarrantsForConsultingFeesMember2019-02-28 00015693292019-03-012020-09-30 0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-02-012019-07-31 0001569329ygyi:StockIssuedToPlacementAgentMember2019-02-012019-07-31 0001569329srt:ScenarioForecastMemberygyi:StockIssuedToPlacementAgentMember2021-02-012021-03-31 0001569329ygyi:AtthemarketEquityOfferingProgramMember2019-01-31 0001569329ygyi:AtthemarketEquityOfferingProgramMember2019-01-012019-01-31 0001569329ygyi:PrivatePlacement2018Member2018-08-012018-10-31 0001569329ygyi:PrivatePlacement2018Member2018-10-31 0001569329ygyi:StockIssuedForAdvisoryFeesMember2018-08-012018-10-31 0001569329ygyi:WarrantsToDebtExchangeDealerMember2019-12-31 0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2018-10-31 0001569329ygyi:PrivatePlacement2018Member2019-01-012019-12-31 0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2020-09-30 0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMemberygyi:ReclassifiedFromDerivativeLiabilityToEquityMember2019-01-01 0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMember2018-10-012018-10-31 0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMember2018-10-31 0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2018-10-31 0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2020-09-30 0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2019-12-31 0001569329ygyi:StockIssuedToDebtExchangeDealerMember2018-10-012018-10-31 0001569329ygyi:WarrantsToDebtExchangeDealerOneMember2018-10-31 0001569329ygyi:WarrantsToDebtExchangeDealerTwoMember2018-10-31 0001569329ygyi:WarrantsToDebtExchangeDealerMember2020-09-30 0001569329ygyi:SeriesBConvertiblePreferredStockMember2018-03-012018-03-31 0001569329ygyi:SeriesBConvertiblePreferredStockMember2018-03-31 0001569329ygyi:WarrantsWithSeriesBOfferingMember2018-03-012018-03-31 0001569329ygyi:WarrantsWithSeriesBOfferingMember2018-03-31 0001569329ygyi:WarrantsWithSeriesBOfferingMember2020-09-30 0001569329ygyi:WarrantsWithSeriesBOfferingMember2019-12-31 0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-03-31 0001569329ygyi:ConversionOfSeriesBPreferredStockIntoCommonStockMember2020-01-012020-03-31 0001569329ygyi:ConversionOfSeriesBPreferredStockIntoCommonStockMember2019-01-012019-12-31 0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-01-012019-09-30 0001569329ygyi:WarrantsWithSeriesCOfferingMember2018-01-012018-12-31 0001569329ygyi:WarrantsWithSeriesCOfferingMember2018-12-31 0001569329us-gaap:SeriesCPreferredStockMember2019-12-31 0001569329ygyi:WarrantsWithSeriesCOfferingMember2019-01-012019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-09-012019-12-31 0001569329srt:WeightedAverageMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2019-09-012019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2019-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2020-01-012020-01-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2020-01-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-09-012020-09-30 0001569329ygyi:CapitalMarketSolutionsLlcMember2018-07-012018-07-31 0001569329ygyi:CapitalMarketSolutionsLlcMember2020-01-012020-09-30 0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-012019-01-31 0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-31 0001569329ygyi:CapitalMarketSolutionsLlcMember2020-01-31 0001569329ygyi:CapitalMarketSolutionsLlcMembersrt:ScenarioForecastMember2021-01-31 0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-012019-09-30 0001569329ygyi:CorinthianPartnersLlcMember2019-08-012019-08-31 0001569329ygyi:GreentreeFinancialGroupIncMember2018-03-012018-03-31 0001569329ygyi:GreentreeFinancialGroupIncMember2019-01-012019-09-30 0001569329ygyi:IbankersMember2019-04-012019-04-30 0001569329ygyi:IbankersMember2020-01-012020-09-30 0001569329ygyi:IbankersMember2019-01-012019-09-30 0001569329ygyi:IgnitionMember2018-04-012018-04-30 0001569329ygyi:IgnitionMember2019-01-012019-09-30 0001569329ygyi:IgnitionMember2019-03-012019-03-31 0001569329ygyi:IgnitionMember2019-03-31 0001569329ygyi:IvanGandrudChevroletIncMember2020-03-012020-03-31 0001569329ygyi:IvanGandrudChevroletIncMember2020-03-31 0001569329ygyi:IvanGandrudChevroletIncMember2020-01-012020-09-30 0001569329ygyi:IvanGandrudChevroletIncMemberygyi:MrDanielManglessMember2020-09-30 0001569329ygyi:BenchmarkCompanyMember2019-08-012019-08-31 0001569329srt:MinimumMember2020-09-30 0001569329srt:MaximumMember2020-09-30 0001569329ygyi:WarrantsWith2014ConvertibleNoteMemberygyi:MrGroverMember2019-06-30 0001569329ygyi:WarrantsWith2014PrivatePlacementMemberygyi:OneJuly2014InvestorMember2019-07-012019-07-31 0001569329ygyi:OneJuly2014InvestorMemberygyi:PrivatePlacement2014Member2019-07-012019-07-31 0001569329ygyi:OneJuly2014InvestorMemberygyi:PrivatePlacement2014Member2019-07-31 0001569329ygyi:WarrantsWith2014PrivatePlacementMemberygyi:OneAugust2014InvestorMember2019-08-012019-08-31 0001569329ygyi:PlacementAgentWarrantsOneMember2014-09-30 0001569329ygyi:PlacementAgentWarrantsTwoMember2014-09-30 0001569329ygyi:PreferredWarrantsMemberygyi:OneInvestorFromSeriesCOfferingMember2019-08-012019-08-31 0001569329ygyi:PreferredWarrantsMemberygyi:OneInvestorFromSeriesCOfferingMember2019-08-31 0001569329us-gaap:CostOfSalesMember2020-07-012020-09-30 0001569329us-gaap:CostOfSalesMember2019-07-012019-09-30 0001569329us-gaap:CostOfSalesMember2020-01-012020-09-30 0001569329us-gaap:CostOfSalesMember2019-01-012019-09-30 0001569329us-gaap:SellingAndMarketingExpenseMember2020-07-012020-09-30 0001569329us-gaap:SellingAndMarketingExpenseMember2019-07-012019-09-30 0001569329us-gaap:SellingAndMarketingExpenseMember2020-01-012020-09-30 0001569329us-gaap:SellingAndMarketingExpenseMember2019-01-012019-09-30 0001569329us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-30 0001569329us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-30 0001569329us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-30 0001569329us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-30 00015693292019-01-012019-12-31 0001569329us-gaap:EmployeeStockOptionMember2020-01-012020-09-30 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:ConsultantsMember2019-08-012019-08-31 00015693292019-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-31 0001569329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-30 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2017-08-012017-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2017-08-012017-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2017-08-012017-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2017-08-012017-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberygyi:SharebasedPaymentArrangementTrancheFourMember2017-08-012017-08-31 00015693292017-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMember2020-08-012020-08-31 0001569329us-gaap:RestrictedStockUnitsRSUMember2019-12-31 0001569329us-gaap:RestrictedStockUnitsRSUMember2020-09-30 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2020-09-30 0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2020-07-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2020-07-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2019-07-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2019-07-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2019-01-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2019-01-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:ThreeVendorsMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:ThreeVendorsMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:ThreeVendorsMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-07-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2020-07-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2020-01-012020-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-07-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2019-07-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-01-012019-09-30 0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:OneVendorMemberygyi:CommercialHempSegmentMember2019-01-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:ThreeCustomersMemberygyi:CommercialCoffeeSegmentMember2020-07-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:TwoCustomersMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:FourCustomersMemberygyi:CommercialCoffeeSegmentMember2019-07-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:OneCustomerMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-07-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:TwoCustomersMemberygyi:CommercialHempSegmentMember2020-07-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-01-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:OneCustomerMemberygyi:CommercialHempSegmentMember2020-01-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-07-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:FourCustomersMemberygyi:CommercialHempSegmentMember2019-07-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-01-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:ThreeCustomersMemberygyi:CommercialHempSegmentMember2019-01-012019-09-30 0001569329ygyi:CommercialHempSegmentMember2019-09-30 0001569329us-gaap:NonUsMember2020-09-30 0001569329us-gaap:NonUsMember2019-12-31 0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2020-07-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2019-07-012019-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2020-01-012020-09-30 0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2019-01-012019-09-30 0001569329country:US2020-07-012020-09-30 0001569329country:US2019-07-012019-09-30 0001569329country:US2020-01-012020-09-30 0001569329country:US2019-01-012019-09-30 0001569329us-gaap:NonUsMember2020-07-012020-09-30 0001569329us-gaap:NonUsMember2019-07-012019-09-30 0001569329us-gaap:NonUsMember2020-01-012020-09-30 0001569329us-gaap:NonUsMember2019-01-012019-09-30 0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMembersrt:ScenarioForecastMember2022-06-17 0001569329ygyi:MrDanielManglessMembersrt:ScenarioForecastMember2021-02-28 0001569329ygyi:AllClaimsRelatedToLawsuitFiledByMrManglessMembersrt:ScenarioForecastMember2021-04-012021-04-30 0001569329srt:ScenarioForecastMemberygyi:SettlementSharesMember2021-04-012021-04-30 0001569329ygyi:CommercialHempSegmentMember2020-04-012020-07-31 0001569329srt:ScenarioForecastMember2021-02-28 0001569329ygyi:DirectSellingSegmentMembersrt:ScenarioForecastMember2021-06-012021-06-30 0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2021-06-012021-06-30 0001569329ygyi:PipeNotes2019Membersrt:ScenarioForecastMember2021-02-28 0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWith2019PipeNotesMember2021-02-012021-02-28 0001569329ygyi:PipeNotes2019Membersrt:ScenarioForecastMember2021-03-31 0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWith2019PipeNotesMember2021-03-012021-03-31 0001569329ygyi:PromissoryNotes2019Membersrt:ScenarioForecastMember2021-02-28 0001569329srt:ScenarioForecastMemberygyi:SharesInConnectionWithPromissoryNotes2019Member2021-02-012021-02-28 0001569329ygyi:WarrantsInConnectionWithPromissoryNotes2019Membersrt:ScenarioForecastMember2021-02-28 0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2022-05-31 0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2022-05-012022-05-31 0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2021-09-30 0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2021-09-012021-09-30 0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2020-12-31 0001569329ygyi:LendingAgreementMembersrt:MinimumMembersrt:ScenarioForecastMember2020-12-31 0001569329ygyi:LendingAgreementMembersrt:MaximumMembersrt:ScenarioForecastMember2020-12-31 0001569329ygyi:LendingAgreementMember2020-05-31 0001569329ygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2021-03-31 0001569329ygyi:TradeAccountsReceivablesMemberygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2020-12-31 0001569329ygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2020-12-31 0001569329ygyi:GrovelandPropertyMembersrt:ScenarioForecastMember2021-05-012021-05-31 0001569329ygyi:MascotteFacilityMembersrt:ScenarioForecastMember2021-10-012021-10-31 0001569329ygyi:ClermontPropertyMembersrt:ScenarioForecastMember2022-02-012022-02-28 0001569329us-gaap:RestrictedStockUnitsRSUMembersrt:ScenarioForecastMember2021-08-012021-08-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2020-07-012020-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2020-10-012020-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2020-01-012021-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2021-01-012021-12-31 0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2022-01-012022-06-15 0001569329ygyi:BeneyouMember2020-01-012020-09-30
 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

 

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______

 

Commission file number: 001-38116

 

YOUNGEVITY INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

90-0890517

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

     

2400 Boswell Road, Chula Vista, CA

 

91914

(Address of Principal Executive Offices)

 

(Zip Code)

 

(619) 934-3980

Registrant’s Telephone Number, Including Area Code

 

Not applicable

Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A N/A N/A

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☐  No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

   

Emerging growth company

 

If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒

 

As of June 17, 2022, the issuer had 34,044,176 shares of its Common Stock, par value $0.001 per share, issued and outstanding.

 

 

 

 

YOUNGEVITY INTERNATIONAL, INC.

TABLE OF CONTENTS

 

   

Page

 

PART I. FINANCIAL INFORMATION

 
     

Item 1.

Financial Statements

 
 

Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) & December 31, 2019

1
 

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)

2
 

Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019 (unaudited)

3
 

Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2020 and 2019 (unaudited)

4
 

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)

8
 

Notes to Condensed Consolidated Financial Statements (unaudited)

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

46

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

61

Item 4.

Controls and Procedures

62
     
 

PART II. OTHER INFORMATION

 
     

Item 1.

Legal Proceedings

65

Item 1A.

Risk Factors

65

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

66

Item 3.

Defaults Upon Senior Securities

66

Item 4.

Mine Safety Disclosures

66

Item 5.

Other Information

67

Item 6.

Exhibits

67

Signatures

  68

 



 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Youngevity International, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

 

   

September 30,

2020

   

December 31,

2019

 

ASSETS

 

(Unaudited)

         

Current Assets

               

Cash and cash equivalents

  $ 1,238     $ 4,463  

Accounts receivable, trade

    3,043       2,902  

Income tax receivable

    81       81  

Inventory

    22,036       22,706  

Prepaid expenses and other current assets

    5,432       3,982  

Total current assets

    31,830       34,134  

Property and equipment, net

    25,189       23,316  

Operating lease right-of-use assets

    6,467       8,386  

Deferred tax assets

    75       75  

Intangible assets, net

    13,726       15,566  

Goodwill

    6,992       6,992  

Other assets

    1,279       1,222  

Total assets

  $ 85,558     $ 89,691  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               

Current Liabilities

               

Accounts payable

  $ 9,405     $ 9,069  

Accrued distributor compensation

    4,167       3,164  

Accrued expenses

    5,732       5,108  

Deferred revenues

    8,527       1,943  

Line of credit

    1,955       2,011  

Other current liabilities

    3,018       2,664  

Operating lease liabilities, current portion

    1,290       1,740  

Finance lease liabilities, current portion

    1,703       736  

Notes payable, net of debt discounts, current portion (Note 3)

    5,340       4,085  

Notes payable, net of debt discounts, current portion

    2,108       191  

Convertible notes payable, net of debt discounts, current portion

    2,927       25  
Short term loans     3,923       -  

Warrant derivative liability

    -       1,542  

Contingent acquisition debt, current portion

    1,341       1,263  

Total current liabilities

    51,436       33,541  

Operating lease liabilities, net of current portion

    5,497       6,646  

Finance lease liabilities, net of current portion

    1,081       408  

Notes payable, net of debt discounts, net of current portion (Note 3)

    392       -  

Notes payable, net of debt discounts, net of current portion

    4,883       6,790  

Convertible notes payable, net of debt discounts, net of current portion

    -       2,675  

Contingent acquisition debt, net of current portion

    5,455       7,348  

Other long-term liabilities

    -       2,115  

Total liabilities

    68,744       59,523  
                 

Commitments and contingencies (Note 11)

                 
                 

StockholdersEquity

               

Preferred stock, $0.001 par value: 5,000,000 shares authorized

               

Series A – 8% convertible preferred stock; 161,135 shares issued and outstanding at September 30, 2020 and December 31, 2019

           

Series B – 5% convertible preferred stock; zero and 129,332 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

           

Series D – 9.75% cumulative redeemable perpetual preferred stock; 590,273 and 578,898 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively; $14,877 liquidation preference at September 30, 2020

           

Common stock, $0.001 par value: 50,000,000 shares authorized; 32,236,994 and 30,274,601 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

    32       30  

Additional paid-in capital

    268,390       265,825  

Accumulated deficit

    (251,154 )     (235,751 )

Accumulated other comprehensive income (loss)

    (454 )     64  

Total stockholders’ equity

    16,814       30,168  

Total Liabilities and StockholdersEquity

  $ 85,558     $ 89,691  

 

See accompanying notes to condensed consolidated financial statements. 

 

 

 

 

 

Youngevity International, Inc. and Subsidiaries

Unaudited Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Revenues

  $ 34,002     $ 33,380     $ 102,525     $ 112,789  

Cost of revenues

    14,248       13,642       42,938       40,522  

Gross profit

    19,754       19,738       59,587       72,267  

Operating expenses

                               

Distributor compensation

    13,262       13,122       40,044       42,509  

Sales and marketing

    3,053       4,432       9,398       11,237  

General and administrative

    8,101       10,663       25,336       38,795  

Total operating expenses

    24,416       28,217       74,778       92,541  

Operating loss

    (4,662

)

    (8,479

)

    (15,191

)

    (20,274

)

Other income (expenses), net

                               

Interest expense, net

    (658

)

    (1,109

)

    (1,917

)

    (3,678

)

Change in fair value of warrant derivative liability

    101       2,457       1,542       4,344  

Loss on modification of warrants

    -       (876

)

    -       (876

)

Total other income (expenses), net

    (557

)

    472       (375

)

    (210

)

Loss before income taxes

    (5,219

)

    (8,007

)

    (15,566

)

    (20,484

)

Income tax benefit

    (147

)

    (133

)

    (163

)

    (61

)

Net loss

    (5,072

)

    (7,874

)

    (15,403

)

    (20,423

)

Preferred stock dividends

    (362

)

    (85

)

    (1,104

)

    (127

)

Net loss attributable to common stockholders

  $ (5,434

)

  $ (7,959

)

  $ (16,507

)

  $ (20,550

)

                                 

Net loss per share, basic

  $ (0.17

)

  $ (0.27

)

  $ (0.52

)

  $ (0.71

)

Net loss per share, diluted (Note 1)

  $ (0.17

)

  $ (0.27

)

  $ (0.52

)

  $ (0.76

)

                                 

Weighted average shares outstanding, basic

    32,233,622       30,035,182       31,479,884       28,924,305  

Weighted average shares outstanding, diluted

    32,233,622       30,039,676       31,479,884       29,003,331  

 

See accompanying notes to condensed consolidated financial statements.

 

 

 

 

Youngevity International, Inc. and Subsidiaries

Unaudited Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2020

   

2019

   

2020

   

2019

 

Net loss

  $ (5,072

)

  $ (7,874

)

  $ (15,403

)

  $ (20,423

)

Foreign currency translation

    (299

)

    9       (518

)

    49  

Total other comprehensive income (loss)

    (299

)

    9       (518

)

    49  

Comprehensive loss

  $ (5,371

)

  $ (7,865

)

  $ (15,921

)

  $ (20,374

)

 

See accompanying notes to condensed consolidated financial statements.

 

 

 

 

 

 

Youngevity International, Inc. and Subsidiaries

Unaudited Condensed Consolidated Statements of Stockholders' Equity

(In thousands, except shares)

 

   

Three Months Ended September 30, 2020

 
   

Preferred Stock

                                                 
   

Series A

   

Series B

   

Series D

   

 

Common Stock

   

Additional Paid-in

   

Accumulated

Other

Comprehensive

   

Accumulated

   

Total Stockholders'

 
   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

    Capital     Loss    

Deficit

   

Equity

 

Balance at June 30, 2020

    161,135     $ -       -     $ -       590,273     $ -       32,216,599     $ 32     $ 268,473     $ (155

)

  $ (246,082

)

  $ 22,268  

Net loss

    -       -       -       -       -       -       -       -       -       -       (5,072

)

    (5,072

)

Foreign currency translation adjustment

    -       -       -       -       -       -       -       -       -       (299

)

    -       (299

)

Issuance of common stock for vesting of restricted stock units

    -       -       -       -       -       -       31,416       -       -       -       -       -  

Shares surrendered for tax obligations for employee restricted stock units

    -       -       -       -       -       -       (9,632

)

    -       -       -       -       -  

Shares surrendered for prior year vesting due to forfeitures for non-employee restricted stock units

    -       -       -       -       -       -       (1,389

)

    -       -       -       -       -  

Fair value of common stock issued related to advance for working capital (recorded in prepaid expenses and other current assets)

    -       -       -       -       -       -       -       -       (101

)

    -       -       (101

)

Dividends on preferred stock

    -       -       -       -       -       -       -       -       (362

)

    -       -       (362

)

Equity-based compensation for services

    -       -       -       -       -       -       -       -       128       -       -       128  

Stock based compensation expense

    -       -       -       -       -       -       -       -       252       -       -       252  

Balance at September 30, 2020

    161,135     $ -       -     $ -       590,273     $ -       32,236,994     $ 32     $ 268,390     $ (454

)

  $ (251,154

)

  $ 16,814  

 

 

 

 

   

Nine Months Ended September 30, 2020

 
   

Preferred Stock

                                                 
   

Series A

   

Series B

   

Series D

   

 

Common Stock

    Additional Paid-in    

Accumulated

Other Income

   

Accumulated

   

Total Stockholders'

 
   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

(Loss)

   

Deficit

   

Equity

 

Balance at December 31, 2019

    161,135     $ -       129,332     $ -       578,898     $ -       30,274,601     $ 30     $ 265,825     $ 64     $ (235,751

)

  $ 30,168  

Net loss

    -       -       -       -       -       -       -       -       -       -       (15,403

)

    (15,403

)

Foreign currency translation adjustment

    -       -       -       -       -       -       -       -       -       (518

)

    -       (518

)

Issuance of common stock for conversion of Series B preferred stock

    -       -       (129,332

)

    -       -       -       258,664       1       -       -       -       1  

Issuance of common stock for vesting of restricted stock units

    -       -       -       -       -       -       39,750       -       -       -       -       -  

Shares surrendered for tax obligations for employee restricted stock units

    -       -       -       -       -       -       (9,632

)

    -       -       -       -       -  

Shares surrendered for prior year vesting due to forfeitures for non-employee restricted stock units

    -       -       -       -       -       -       (1,389

)

    -       -       -       -       -  

Issuance of common stock for debt financing, net of issuance costs

    -       -       -       -       -       -       50,000       -       65       -       -       65  

Preferred stock-Series D issued through Underwritten Registered Public Offering, net

    -       -       -       -       11,375       -       -       -       233       -       -       233  

Fair value of common stock issued related to Nica Hemp Project

    -       -       -       -       -       -       1,500,000       1       2,489       -       -       2,490  

Fair value of common stock issued related to advance for working capital (recorded in prepaid expenses and other current assets)

    -       -       -       -       -       -       -       -       (324

)

    -       -       (324

)

Dividends on preferred stock

    -       -       -       -       -       -       -       -       (1,104

)

    -       -       (1,104

)

Equity-based compensation for services

    -       -       -       -       -       -       125,000       -       429       -       -       429  

Stock based compensation expense

    -       -       -       -       -       -       -       -       777       -       -       777  

Balance at September 30, 2020

    161,135     $ -       -     $ -       590,273     $ -       32,236,994     $ 32     $ 268,390     $ (454

)

  $ (251,154

)

  $ 16,814  

 

 

 

 

Youngevity International, Inc. and Subsidiaries

Unaudited Condensed Consolidated Statements of Stockholders' Equity

(In thousands, except shares)

 

   

Three Months Ended September 30, 2019

 
   

Preferred Stock

                                                 
   

Series A

   

Series B

   

Series D

   

Common Stock

   

Additional Paid-in

   

Accumulated Other Comprehensive Income

   

Accumulated

   

Total Stockholders'

 
   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

(Loss)

   

Deficit

   

Equity

 

Balance at June 30, 2019

    161,135     $ -       129,437     $ -       -     $ -       29,316,445     $ 29     $ 247,935     $ (5

)

  $ (196,312

)

  $ 51,647  

Net loss

    -       -       -       -       -       -       -       -       -       -       (7,874

)

    (7,874

)

Foreign currency translation adjustment

    -       -       -       -       -       -       -       -       -       9       -       9  

Issuance of common stock from exercise of stock options and warrants

    -       -       -       -       -       -       790,942       1       3,630       -       -       3,631  

Issuance of common stock, related to ATM Financing

    -       -       -       -       -       -       16,524       -       96       -       -       96  

Issuance of common stock for services

    -       -       -       -       -       -       75,600       -       478       -       -       478  

Issuance of warrants for services

    -       -       -       -       -       -       -       -       414       -       -       414  

Issuance of common stock for inducement shares

    -       -       -       -       -       -       64,250       -       478       -       -       478  

Preferred stock-Series D issued through Underwritten Registered Public Offering, net

    -       -       -       -       333,500       -       -       -       7,323       -       -       7,323  

Vesting of Restricted Stock Units

    -       -       -       -       -       -       1,389       -       -       -       -       -  

Warrant issued upon vesting for services

    -       -       -       -       -       -       -       -       270       -       -       270  

Issuance of common stock for conversion of Series B preferred stock

    -       -       (105

)

    -       -       -       210       -       -       -       -       -  

Issuance of common stock for convertible note financing, net of issuance costs

    -       -       -       -       -       -       5,000       -       23       -       -       23  

Release of warrant liability upon reclassification of liability to equity

    -       -       -       -       -       -       -       -       211       -       -       211  

Dividends on preferred stock

    -       -       -       -       -       -       -       -       (85

)

    -       -       (85

)

Stock based compensation expense

    -       -       -       -       -       -       -       -       661       -       -       661  

Balance at September 30, 2019

    161,135     $ -       129,332     $ -       333,500     $ -       30,270,360     $ 30     $ 261,434     $ 4     $ (204,186

)

  $ 57,282  

 

 

 

 

   

Nine Months Ended September 30, 2019

 
   

Preferred Stock

                                                 
   

Series A

   

Series B

   

Series D

   

Common Stock

   

Additional Paid-in

   

Accumulated Other Comprehensive Income

   

Accumulated

   

Total Stockholders'

 
   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

(Loss)

   

Deficit

   

Equity

 

Balance at December 31, 2018

    161,135     $ -       129,437     $ -       -     $ -       25,760,708     $ 26     $ 206,757     $ (45

)

  $ (183,763

)

  $ 22,975  

Net loss

    -       -       -       -       -       -       -       -       -       -       (20,423

)

    (20,423

)

Foreign currency translation adjustment

    -       -       -       -       -       -       -       -       -       49       -       49  

Issuance of common stock from exercise of stock options and warrants

    -       -       -       -       -       -       1,164,102       2       5,371       -       -       5,373  

Issuance of common stock, related to ATM Financing

    -       -       -       -       -       -       17,524       -       102       -       -       102  

Issuance of common stock for services

    -       -       -       -       -       -       250,600       -       1,466       -       -       1,466  

Issuance of warrants for services

    -       -       -       -       -       -       -       -       414       -       -       414  

Issuance of common stock for inducement shares

    -       -       -       -       -       -       64,250       -       478       -       -       478  

Preferred stock-Series D issued through Underwritten Registered Public Offering, net

    -       -       -       -       333,500       -       -       -       7,323       -       -       7,323  

Vesting of Restricted Stock Units

    -       -       -       -       -       -       1,389       -       -       -       -       -  

Warrant issued upon vesting for services

    -       -       -       -       -       -       -       -       2,196       -       -       2,196  

Issuance of common stock for conversion of Series B preferred stock

    -       -       (105

)

    -       -       -       210       -       -       -       -       -  

Issuance of common stock for true-up shares

    -       -       -       -       -       -       44,599       -       281       -       -       281  

Issuance of common stock for debt financing, net of issuance costs

    -       -       -       -       -       -       40,000       -       350       -       -       350  

Issuance of common stock, Private Placement, net of issuance costs

    -       -       -       -       -       -       505,000       -       3,125       -       -       3,125  

Issuance of common stock for convertible note financing, net of issuance costs

    -       -       -       -       -       -       77,250       -       451       -       -       451  

Issuance of common stock related to advance for working capital (note receivable) net of settlement of debt

    -       -       -       -       -       -       295,910       1       2,308       -       -       2,309  

Issuance of common stock for related to purchase of land - H&H

    -       -       -       -       -       -       153,846       -       1,200       -       -       1,200  

Issuance of common stock for related to purchase of trademark - H&H

    -       -       -       -       -       -       100,000       -       750       -       -       750  

Issuance of common stock for acquisition of Khrysos

    -       -       -       -       -       -       1,794,972       1       13,999       -       -       14,000  

Release of warrant liability upon warrant exercises

    -       -       -       -       -       -       -       -       1,077       -       -       1,077  

Release of warrant liability upon reclassification of liability to equity

    -       -       -       -       -       -       -       -       1,494       -       -       1,494  

Dividends on preferred stock

    -       -       -       -       -       -       -       -       (127

)

    -       -       (127

)

Stock based compensation expense

    -       -       -       -       -       -       -       -       12,418       -       -       12,418  

Balance at September 30, 2019

    161,135     $ -       129,332     $ -       333,500     $ -       30,270,360     $ 30     $ 261,434     $ 4     $ (204,186

)

  $ 57,282  

 

 

 

 

Youngevity International, Inc. and Subsidiaries

Unaudited Condensed Consolidated Statements of Cash Flows

(In thousands)

 

   

Nine Months Ended

September 30,

 
   

2020

   

2019

 

Cash Flows from Operating Activities:

               

Net loss

  $ (15,403

)

  $ (20,423

)

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    3,808       4,199  

Stock-based compensation expense

    777       12,418  

Equity-based compensation for services

    1,132       3,982  

Amortization of debt discounts and issuance costs

    1,099       924  

Change in fair value of warrant derivative liability

    (1,542

)

    (4,344

)

Change in fair value of contingent acquisition debt

    (1,640

)

    (911

)

Change in allowance for other receivable (Note 3)

    (324

)

    -  

Change in allowance for notes receivable (Note 3)

    337       -  

Change in inventory reserve

    (84

)

    889  

Changes in allowance for accounts receivable

    (30

)

    -  

Gain on debt extinguishment

    (48

)

    -  

Loss on disposal of property and equipment

    101       -  

Loss on impairment of inventory

    200       -  

Non-cash operating lease expense

    1,919       -  

Stock issuance for true-up shares

    -       281  

Loss on modification of warrants

    -       876  

Deferred taxes

    -       73  

Changes in operating assets and liabilities, net of effect from business combinations:

               

Accounts receivable

    (111

)

    (5,389

)

Inventory

    554       (958

)

Prepaid expenses and other current assets

    337       (1,411

)

Income taxes receivable

    -       (233

)

Other assets

    (395

)

    -  

Accounts payable

    336       454  

Accrued distributor compensation

    1,003       (37

)

Deferred revenues

    6,584       (307

)

Accrued expenses and other liabilities

    982       2,155  

Operating lease liabilities

    (1,599

)

    -  

Other long-term liabilities

    (68 )     -  

Net Cash Used in Operating Activities

    (2,075 )     (7,762 )
                 

Cash Flows from Investing Activities:

               

Acquisitions, net of cash acquired

    -       (925

)

Purchases of property and equipment

    (3,515

)

    (5,177

)

Net Cash Used in Investing Activities

    (3,515

)

    (6,102

)

                 

Cash Flows from Financing Activities:

               

Proceeds from issuance of promissory notes, net of offering costs

    1,000       5,125  

Proceeds from private placement of common stock, net of offering costs

    -       2,871  

Proceeds from the exercise of stock options and warrants, net

    -       5,214  

Proceeds from at-the-market-offering transaction

    -       102  

Proceeds from the issuance of preferred stock – series D, net of offering costs

    233       7,323  

Proceeds from short-term debt

    3,923       -  

Payments from line of credit, net

    (56

)

    (275

)

Payments of notes payable

    (77

)

    (108

)

Payments of convertible notes payable

    (25

)

    (568

)

Payments of contingent acquisition debt

    (175

)

    (333

)

Payments of finance leases

    (832

)

    (1,099

)

Payments of dividends

    (1,108

)

    (46

)

Net Cash Provided by Financing Activities

    2,883       18,206  

Foreign Currency Effect on Cash

    (518

)

    49  

Net decrease in cash and cash equivalents

    (3,225

)

    4,391  

Cash and Cash Equivalents, Beginning of Period

    4,463       2,879  

Cash and Cash Equivalents, End of Period

  $ 1,238     $ 7,270  
                 

Supplemental Disclosures of Cash Flow Information

               

Cash paid during the period for:

               

Interest

  $ 883     $ 2,641  

Income taxes

  $ 30     $ 164  
                 

Supplemental Disclosures of Noncash Investing and Financing Activities

               

Purchases of property and equipment funded by finance leases

  $ 427     $ 42  

Purchases of property and equipment funded by mortgage agreements

  $ -     $ 977  

Fair value of stock issued for Nica Hemp Project (Note 3)

  $ 2,490     $ -  

Issuance of common stock for promissory note financing (Note 10)

  $ 65     $ -  

Change in fair value of common stock issued for in relation to advance for working capital (Note 3)

  $ 324     $ -  

Fair value of stock issued in connection with the acquisition of Khrysos Global, Inc. (Note 2)

  $ -     $ 14,000  

Fair value of stock issued for services (Note 10)

  $ -     $ 1,880  

Fair value of warrant issued for services, vested portion (Note 10)

  $ -     $ 2,196  

Fair value of stock issued for property and equipment (land)

  $ -     $ 1,200  

Fair value of stock issued for purchase of intangibles (tradename)

  $ -     $ 750  

Fair value of stock issued for note receivable, net of debt settlement

  $ -     $ 2,309  

Issuance of common stock for the noncash exercise of warrants

  $ -     $ 157  

Dividends declared but not paid at the end of period (Note 10)

  $ 120     $ 83  

 

See accompanying notes to condensed consolidated financial statements.

 

 

Youngevity International, Inc. and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

Note 1. Description of Business and Basis of Presentation

 

Description of Business

 

Youngevity International, Inc. (the “Company”) operates in three segments: (i) the direct selling segment where products are offered through a global distribution network of preferred customers and distributors, (ii) the commercial coffee segment where products are sold directly to businesses and (iii) the commercial hemp segment where the Company manufactures proprietary systems to provide end-to-end extraction and processing of hemp feed stock into hemp oil and hemp extracts, oil extraction services, and contract manufacturing services.

 

Information on the operations of the Company’s three segments is as follows:

 

 

The direct selling segment is operated through the Company’s three domestic subsidiaries, AL Global Corporation, 2400 Boswell LLC, and Youngevity Global LLC, and twelve foreign subsidiaries:

 

 

Youngevity Australia Pty. Ltd.,

 

Youngevity NZ, Ltd.,

 

Youngevity Mexico S.A. de CV,

 

Youngevity Russia, LLC,

 

Youngevity Israel, Ltd.,

 

Youngevity Europe SIA (Latvia),

 

Youngevity Colombia S.A.S,

 

Youngevity International Singapore Pte. Ltd.,

 

Mialisia Canada, Inc.,

 

Youngevity Global LLC, Taiwan Branch,

 

Youngevity Global LLC, Philippine Branch, and

 

Youngevity International (Hong Kong).

 

 

 

The Company also operate in Indonesia, Malaysia, and Japan through its sales force of independent distributors.

 

 

The commercial coffee business is operated through the Company’s wholly-owned subsidiary, CLR Roasters LLC (“CLR”) and its wholly-owned subsidiary, Siles Plantation Family Group S.A. (“Siles”).

 

The commercial hemp business is operated through the Company’s wholly-owned subsidiary, Khrysos Industries, Inc., a Delaware corporation (“KII”). KII acquired the assets of Khrysos Global Inc., a Florida corporation (“Khrysos Global”), in February 2019 and the wholly-owned subsidiaries of Khrysos Global, INXL Laboratories, Inc., a Florida corporation (“INXL”) and INX Holdings, Inc., a Florida corporation (“INXH”).

 

In the following text, the term “the Company” refers collectively to the Company and its subsidiaries.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, certain information and footnote disclosures, normally included in financial statements prepared in accordance with generally accepted accounting principles, have been condensed or omitted pursuant to such rules and regulations.

 

Youngevity International, Inc. (the “Company”) consolidates all wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

The condensed consolidated financial statements presented as of September 30, 2020 and for the three and nine months ended September 30, 2020 and 2019 are unaudited. In the opinion of management, these unaudited condensed consolidated financial statements reflect all normal recurring and other adjustments necessary for a fair presentation, and to make the financial statements not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on June 25, 2021. The results for interim periods are not necessarily indicative of the results for the entire year.

 

 

 

 

Segment Information

 

The Company has three reportable segments: direct selling, commercial coffee, and commercial hemp. The direct selling segment develops and distributes health and wellness products through its global independent direct selling network also known as multi-level marketing. The commercial coffee segment is engaged in coffee roasting and distribution, specializing in gourmet coffee. The commercial hemp segment manufactures proprietary systems to provide end-to-end extraction and processing that allow for the conversion of hemp feed stock into hemp oil and hemp extracts. The determination that the Company has three reportable segments is based upon the guidance set forth in Accounting Standards Codification (“ASC”) Topic 280, “Segment Reporting.” 

 

During the three months ended September 30, 2020, the Company derived approximately 92.1% of its revenue from its direct selling segment and 7.3% of its revenue from its commercial coffee segment and 0.6% from the commercial hemp segment. During the three months ended September 30, 2019, the Company derived approximately 90.6% of its revenue from its direct selling segment, 8.8% of its revenue from its commercial coffee segment and 0.6% from the commercial hemp segment.

 

During the nine months ended September 30, 2020, the Company derived approximately 90.5% of its revenue from its direct selling segment and 8.5% of its revenue from its commercial coffee segment and 1.0% from the commercial hemp segment. During the nine months ended September 30, 2019, the Company derived approximately 84.9% of its revenue from its direct selling segment, 14.6% of its revenue from its commercial coffee segment and 0.5% from the commercial hemp segment.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense for each reporting period. Estimates are used in accounting for, among other things, allowances for doubtful accounts, deferred taxes and related valuation allowances, fair value of derivative liabilities, uncertain tax positions, loss contingencies, fair value of options granted under the Company’s stock-based compensation plan, fair value of assets and liabilities acquired in business combinations, finance leases, asset impairments, estimates of future cash flows used to evaluate impairments, useful lives of property, equipment and intangible assets, value of contingent acquisition debt, inventory obsolescence, and sales returns.  

 

Actual results may differ from previously estimated amounts and such differences may be material to the consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected prospectively in the period they occur.

 

Liquidity and Going Concern

 

The accompanying consolidated financial statements have been prepared and presented on a basis assuming the Company will continue as a going concern. The Company has sustained significant net losses during the nine months ended September 30, 2020 and 2019 of approximately $15,403,000 and $20,423,000, respectively. Net cash used in operating activities was approximately $2,075,000 and $7,762,000 for the nine months ended September 30, 2020 and 2019, respectively.

 

Management has assessed the Company’s ability to continue as a going concern and concluded that additional capital will be required during the twelve-months subsequent to the filing date of this Quarterly Report on Form 10-Q. The timing of when the additional capital will be required is uncertain and highly dependent on factors discussed below. There can be no assurance that the Company will be able to execute license or purchase agreements or to obtain equity or debt financing, or on terms acceptable to it. Factors within and outside the Company’s control could have a significant bearing on its ability to obtain additional financing. As a result, management has determined that there are material uncertainties that raise substantial doubt upon the Company’s ability to continue as a going concern.

 

The Company has and continues to take actions to alleviate the cash used in operations. During the nine months ending September 30 2020, the Company reported total revenue of approximately $102,525,000 a decrease of approximately 9.1% compared to the same period a year ago. The Company continues to focus on revenue growth, but the Company cannot make assurances that revenues will grow. Additionally, the Company has plans to make the necessary cost reductions and to reduce non-essential expenses, including international operations that are not performing well to help alleviate the cash used in operating activities.

 

- 10-

 

The outbreak of COVID-19 and resulting pandemic resulted in significant contraction of economies around the world and interrupted global supply chains as many governments issued stay-at-home orders to combat COVID-19. The outbreak of COVID-19 also impacted the Company’s ability to properly staff and maintain its domestic and international warehousing operations due to stay-at-home orders issued within various locations where the Company operates warehouse and shipping operations. The Company took actions to mitigate the impact but cannot assert that future stay-at-home orders or further restrictive orders will not have an impact on future operations. The Company experienced changes in product mix demand, with demand increasing toward health-oriented products and weakening for non-health related products. Such changes in demand may have a significant impact on revenues, margins and net operating profit in the future. The outbreak also impacted the Company’s ability to obtain some ingredients and packaging as well as ship products in some markets. The Company’s supply chain and logistics incurred some interruptions and cost impacts to date, and the Company could experience more significant interruptions and cost impacts. The Company’s suppliers of raw material and supplies have and could continue to be impacted by geopolitical events, such as the war in Ukraine, thus interrupting the Company’s supply chain. Additionally, the Company’s customers may experience interruptions from other suppliers that could cause a customer to delay or cancel orders. These factors and other events have negatively impacted the Company’s sales and operations and will likely continue to negatively affect the Company’s business and financial results. The Company is unable to predict the possible future effect on the demand for products sold by the Company, and the related revenues, margins and operating profit due to these events.

 

In addition, the outbreak of the COVID-19 coronavirus has disrupted the Company’s operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in the Company’s office or other workplace, or due to quarantines. COVID-19 illness could also impact members of the Company’s board of directors resulting in absenteeism from meetings of the directors or committees of directors and making it more difficult to convene the quorums of the full board of directors or its committees needed to conduct meetings for the management of the Company’s affairs.

 

The Company continues to seek and obtain equity or debt financing on terms that are acceptable to the Company. Depending on market conditions, there can be no assurance that additional capital will be available when needed or that, if available, it will be obtained on terms favorable to the Company or to its stockholders.

 

These financial statements have been prepared on a going concern basis, which asserts the Company has the ability in the near term to continue to realize its assets and discharge its liabilities and commitments in a planned manner giving consideration to the above and expected possible outcomes. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Within the current operating environment due to the declared national emergency, related to COVID 19 combined with the management plans described above the Company cannot assert that the doubt of the Company’s ability to continue as a going concern has been substantially alleviated. Conversely, if the going concern assumption is not appropriate, adjustments to the carrying amounts of the Company’s assets, liabilities, revenues, expenses and balance sheet classifications may be necessary, and these adjustments could be material.

 

 

 

 

Actual results may differ from previously estimated amounts and such differences may be material to the consolidated financial statements. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected prospectively in the period they occur.

 

Cash and Cash Equivalents

 

The Company considers only its monetary liquid assets with original maturities of three months or less as cash and cash equivalents.

 

Revenue Recognition

 

The Company recognizes revenue from product sales when the following five steps are completed: i) Identify the contract with the customer; ii) Identify the performance obligations in the contract; iii) Determine the transaction price; iv) Allocate the transaction price to the performance obligations in the contract; and v) Recognize revenue when (or as) each performance obligation is satisfied.

 

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Revenue is recognized net of allowances for returns and any taxes collected from customers, which are subsequently remitted to governmental authorities.

 

The transaction price for all sales is based on the price reflected in the individual customer's contract or purchase order.  Variable consideration has not been identified as a significant component of the transaction price for any of our transactions.

 

Independent distributors receive compensation which is recognized as distributor compensation in the Company’s consolidated statements of operations. Due to the short-term nature of the contract with the customers, the Company accrues all distributor compensation expense in the month earned and pays the compensation the following month.

 

The Company also charges fees to become a distributor, and earn a position in the network genealogy, which are recognized as revenue in the period received. The Company’s distributors are required to pay a one-time enrollment fee and receive a welcome kit specific to that country or region that consists of forms, policy and procedures, selling aids, access to our distributor website and a genealogy position with no down line distributors.

 

The Company has determined that most contracts will be completed in less than one year. For those transactions where all performance obligations will be satisfied within one year or less, the Company is applying the practical expedient outlined in ASC 606-10-32-18. The practical expedient allows the Company not to adjust promised consideration for the effects of a significant financing component if the Company expects at contract inception the period between when the Company transfers the promised good or service to a customer and when the customer pays for that good or service will be one year or less. For those transactions that are expected to be completed after one year, the Company has assessed that there are no significant financing components because any difference between the promised consideration and the cash selling price of the good or service is for reasons other than the provision of financing.

 

Revenue recognition by segment is as follows:

 

Direct Selling. Direct distribution sales are made through the Company’s network (direct selling segment), which is a web-based global network of customers and distributors. The Company’s independent sales force markets a variety of products to an array of customers, through friend-to-friend marketing and social networking. The Company considers itself to be an e-commerce company whereby personal interaction is provided to customers by its independent sales network. Sales generated from direct distribution includes; health and wellness, beauty product and skin care, scrap booking and story booking items, packaged food products and other service-based products.

 

Revenue is recognized when the Company satisfies its performance obligations under the contract. The Company recognizes revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of the Company’s contracts have a single performance obligation and are short term in nature. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.

 

 

 

Commercial Coffee - Roasted Coffee. The Company engages in the commercial sale of roasted coffee through CLR, which is sold under a variety of private labels through major national sales outlets and to customers including cruise lines and office coffee service operators, and under its own Café La Rica brand, Josie’s Java House Brand, Javalution brands and Café Cachita as well as through its distributor network within the direct selling segment.

 

Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement, typically, FOB shipping point. At this point the customer has a present obligation to pay, takes physical possession of the product, takes legal title to the product, bears the risks and rewards of ownership, and as such, revenue will be recognized at this point in time. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.

 

Commercial Coffee - Green Coffee. The commercial coffee segment includes the sale of green coffee beans, which are sourced from the Nicaraguan rainforest.

 

Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement, typically, FOB shipping point. At this point the customer has a present obligation to pay, takes physical possession of the product, takes legal title to the product, bears the risks and rewards of ownership, and as such, revenue will be recognized at this point in time. Revenues where the Company sells green coffee beans that it has milled and where the Company has determined it is the agent with regard to the green coffee beans is recorded at net or recorded to reflect only the milling services provided. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.

 

Commercial Hemp. In the commercial hemp segment, the Company develops, manufactures, and sells equipment and related services to customers which enable them to extract CBD oils from hemp stock. The Company provides hemp growers, feedstock suppliers, and CBD crude oil producers the use of equipment, intellectual capital, production consultancy, tolling services, and wholesale CBD channel sales capabilities. The Company is also engaged in hemp-based CBD extraction technology including tolling processing which converts hemp crude oil to hemp extracts such as full spectrum distillate, and cannabinoid isolate (CBD, cannabigerol or CBG, cannabinol or CBN). The Company offers customers turnkey manufacturing solutions in extraction services and end-to-end processing systems. In addition, the Company provides a broad range of capabilities in regard to formulation, quality control, and testing standards with our CBD products, including potency analysis for its supply partners of hemp derived CBD products. The Company follows all guidelines for Current Good Manufacturing Practices ("CGMP") and our hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm that the cannabinoid content meets strict company standards. 

 

Revenue is recognized when the title and risk of loss is passed to the customer under the terms of the shipping arrangement, typically, FOB shipping point. At this point the customer has a present obligation to pay, takes physical possession of the product, takes legal title to the product, bears the risks and rewards of ownership, and as such, revenue will be recognized at this point in time. Sales taxes in domestic and foreign jurisdictions are collected from customers and remitted to governmental authorities, all at the local level, and are accounted for on a net basis and therefore are excluded from revenues.

 

Contract Balances. Timing of revenue recognition may differ from the timing of invoicing to customers. The Company records contract assets when performance obligations are satisfied prior to invoicing.

 

Contract liabilities are reflected as deferred revenues and customer deposits in accrued expenses, deferred revenue, other current liabilities and other long-term liabilities on the Company’s consolidated balance sheets. Contract liabilities relate to payments invoiced or received in advance of completion of performance obligations and are recognized as revenue upon the fulfillment of performance obligations. The Company recognizes deferred revenue in its direct selling, commercial coffee and commercial coffee segments.

 

In January 2020, the Company introduced a rewards program in the direct selling segment where its distributors earn points awards that can be redeemed for the future product purchases. These points awards are earned by the distributors through the purchase of products or through actions and participation in non-product purchase activities. The Company records the points earned through the purchase of product by reducing revenue and creates the liability at the point of purchase. Award points earned through non-product purchasing activities are recorded as marketing expenses and creates the liability at the time the distributor performs the non-revenue activity.

 

 

 

The deferred revenue related to Heritage Maker’s product line obligation for points purchased by customers represents cash payments received that have not yet been redeemed for product. Revenue is recognized when customers redeem the points, and the product is shipped. Deferred revenues related to pre-enrollment in conventions and distributor events primarily related to the Company’s 2020 events. The Company does not recognize revenue until the conventions or distributor events have occurred.

 

The Company also records deferred revenue within its direct selling, commercial coffee and commercial hemp segments related to payments made by customers for unshipped orders.

 

Deferred costs relate to Heritage Makers prepaid commissions are recorded in prepaid expenses and other current assets on the Company’s consolidated balance sheets and recognized in expense at the time the related revenue is recognized.

 

Plantation Costs

 

The Company’s commercial coffee segment includes the results of Siles, which is comprised of (i) a 500-acre coffee plantation and (ii) a dry-processing facility located on 26 acres, both of which are located in Matagalpa, Nicaragua. Siles is a wholly-owned subsidiary of CLR, and the results of CLR include the depreciation and amortization of capitalized costs, development and maintenance and harvesting costs of Siles. In accordance with GAAP, plantation maintenance and harvesting costs for commercially producing coffee farms are charged against earnings when sold. Deferred harvest costs accumulate and are capitalized throughout the year and are expensed over the remainder of the year as the coffee is sold. The difference between actual harvest costs incurred and the amount of harvest costs recognized as expense is recorded as either an increase or decrease in deferred harvest costs, which is reported as an asset and included with prepaid expenses and other current assets in the condensed consolidated balance sheets. Once the harvest is complete, the harvest costs are then recognized as the inventory value. There were no deferred costs associated with the harvest at September 30, 2020. Deferred costs associated with the harvest at December 31, 2019 were approximately $350,000.

 

Stock-based Compensation

 

The Company accounts for stock-based compensation in accordance with ASC Topic 718,CompensationStock Compensation,” which establishes accounting for equity instruments exchanged for services from employees and non-employees. Under such provisions, cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense net of forfeitures, under the straight-line method, over the vesting period of the equity grant. Forfeitures are recorded as they occur.

 

The Company uses the Black-Scholes to estimate the fair value of stock options. The use of a valuation model requires the Company to make certain assumptions with respect to selected model inputs. Expected volatility is calculated based on the historical volatility of the Company’s stock price over the expected term of the option. The expected life is based on the contractual life of the option and expected employee exercise and post-vesting employment termination behavior. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of the grant.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC Topic 740, "Income Taxes," under the asset and liability method which includes the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this approach, deferred taxes are recorded for the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial statement and tax basis of assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. The effects of future changes in income tax laws or rates are not anticipated.

 

Income taxes for the interim periods are computed using the effective tax rates estimated to be applicable for the full fiscal year, as adjusted for any discrete taxable events that occur during the period.

 

The Company files income tax returns in the U.S. on a federal basis and in many U.S. state and foreign jurisdictions. Certain tax years remain open to examination by the major taxing jurisdictions to which the Company is subject.

 

 

 

Commitments and Contingencies

 

The Company is from time to time, the subject of claims and suits arising out of matters related to the Company’s business. The Company is party to litigation at the present time and may become party to litigation in the future. In general, litigation claims can be expensive, and time consuming to bring or defend against and could result in settlements or damages that could significantly affect financial results. It is not possible to predict the final resolution of the current litigation to which the Company is party to, and the impact of certain of these matters on the Company’s business, results of operations, and financial condition could be material. Regardless of the outcome, litigation has adversely impacted the Company’s business because of defense costs, diversion of management resources and other factors.

 

Basic and Diluted Net Loss Per Share

 

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed by dividing net loss attributable to common stockholders by the sum of the weighted-average number of common shares outstanding during the period and the weighted-average number of dilutive common share equivalents outstanding during the period, using the treasury stock method. Dilutive common share equivalents are comprised of stock options, restricted stock, warrants, convertible preferred stock and common stock associated with the Company's convertible notes based on the average stock price for each period using the treasury stock method. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive.

 

In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. Potentially dilutive securities for the periods ended September 30, 2020 and 2019 were 10,594,784 and 10,988,108 shares, respectively.

 

   

September 30,

 
   

2020

   

2019

 
   

(unaudited)

   

(unaudited)

 

Warrants

    5,266,187       6,238,182  

Preferred stock conversions

    22,786       275,600  

Principal conversions on convertible notes

    309,000       312,571  

Stock options

    4,567,368       3,705,644  

Restricted stock units

    429,443       456,111  

Total

    10,594,784       10,988,108  

 

The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of such securities are dilutive to loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of the warrants, net of tax from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. During the three and nine months ended September 30, 2019, the Company recorded net of tax gain of $27,000 and $1,529,000, respectively, on the valuation of the warrant derivative liability which had a dilutive impact on loss per share.

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2020

   

2019

   

2020

   

2019

 
   

(unaudited)

   

(unaudited)

   

(unaudited)

   

(unaudited)

 

Loss per ShareBasic

                               

Numerator for basic loss per share

  $ (5,434,000

)

  $ (7,959,000

)

  $ (16,507,000

)

  $ (20,550,000

)

Denominator for basic loss per share

    32,233,622       30,035,182       31,479,884       28,924,305  

Loss per common share - basic

  $ (0.17

)

  $ (0.27

)

  $ (0.52

)

  $ (0.71

)

                                 

Loss per Share - Diluted

                               

Numerator for basic loss per share

  $ (5,434,000

)

  $ (7,959,000

)

  $ (16,507,000

)

  $ (20,550,000

)

Adjust: Fair value of dilutive warrants outstanding

    -       (27,000

)

    -       (1,529,000

)

Numerator for dilutive loss per share

  $ (5,434,000

)

  $ (7,986,000

)

  $ (16,507,000

)

  $ (22,079,000

)

                                 

Denominator for basic loss per share

    32,233,622       30,035,182       31,479,884       28,924,305  

Plus: Incremental shares underlying “in the money” warrants outstanding

    -       4,494       -       79,026  

Denominator for dilutive loss per share

    32,233,622       30,039,676       31,479,884       29,003,331  

Loss per common share - diluted

  $ (0.17

)

  $ (0.27

)

  $ (0.52

)

  $ (0.76

)

 

 

 

 

Recently Issued and Adopted Accounting Pronouncements

 

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the Company’s financial statements. During the nine months ended September 30, 2020, the Company did not adopt any accounting pronouncements. 

 

 

Note 2. Acquisitions and Business Combinations

 

During 2019, the Company entered into two acquisitions which are detailed below. The acquisitions were conducted to allow the Company to enter into the hemp market and expand the Company’s distributor network within the direct selling segment, enhance and expand its product portfolio, and diversify its product mix. As a result of the Company’s business combinations, the Company’s distributors and customers will have access to the acquired company’s products and acquired company’s distributors and customers will gain access to products offered by the Company. 

 

As such, the major purpose for the business combinations was to increase revenue and profitability. The acquisitions were structured as asset purchases which resulted in the recognition of certain intangible assets.

 

During the nine months ended September 30, 2020, the Company did not have any acquisitions.

 

2019 Acquisitions

 

BeneYOU

 

On October 31, 2019, the Company entered into an asset purchase agreement with an effective date of November 1, 2019, with BeneYOU, LLC, a Utah limited liability company (“BeneYOU”), and Ryan Anderson (the “BeneYOU Representing Party”), for the Company to acquire certain assets of BeneYOU to including all of the outstanding equity of BeneYOU Holding, LLC, a Utah limited liability company (“BeneYOU Holding”), collectively “BeneYOU”. In accordance with the asset purchase agreement, the Company also acquired BeneYOU’s customer and distributor organization lists, all intellectual property, product formulations, products, product packaging, product registrations, licenses, marketing materials, sales tools and swag, and all saleable inventory. BeneYOU’s flagship brand Jamberry has an extensive line of nail products with a core competency in social selling, and two other brands including Avisae which focuses on the gut health and the M.Global brand of products that includes hydration products.

 

The Company is obligated to make monthly payments based on a percentage of the BeneYOU distributor revenue derived from sales of the Company’s products and a percentage of royalty revenue derived from sales of BeneYOU products until the earlier of the date that is ten years from the closing date or such time as the Company has paid to BeneYOU aggregate cash payments of the BeneYOU distributor revenue and royalty revenue equal to the maximum aggregate purchase price of $3,500,000. In addition, the Company paid an acquisition liability payment of $200,000 on the closing date, which reduced the maximum aggregate purchase price to $3,300,000.

 

The contingent consideration’s estimated fair value at the date of acquisition was approximately $2,648,000 as determined by management using a discounted cash flow methodology. The acquisition related costs, such as legal costs and other professional fees were minimal and expensed as incurred.

 

The purchase agreement contains customary representations, warranties and covenants of the Company, BeneYOU and the BeneYOU Representing Party. Subject to certain customary limitations the BeneYOU Representing Party have agreed to indemnify the Company and BeneYOU against certain losses related to, among other things, breaches of the BeneYOU Representing Party’s representations and warranties, certain specified liabilities and the failure to perform covenants or obligations under the purchase agreement.

 

The Company recorded the fair value at the date of acquisition of the acquired tangible and intangible assets and liabilities as follows (in thousands):

 

Contingent consideration

  $ 2,648  

Aggregate purchase price

  $ 2,648  

 

The following table summarizes the fair values of the assets acquired and liabilities assumed in November 2019 (in thousands):

 

Current assets (excluding inventory)

  $ 408  

Inventory (net of $469 reserve)

    441  

Trademarks and trade name

    343  

Distributor organization

    1,175  

Customer relationships

    44  

Non-compete agreement

    277  

Goodwill

    669  

Current liabilities

    (709

)

Net assets acquired

  $ 2,648  

 

The reported fair value of intangible assets acquired of $1,839,000 was determined through the use of a third-party valuation firm using various income and cost approach methodologies. Specifically, the intangibles identified in the acquisition were trademarks and trade name, distributor organization, customer relationships and non-compete agreement and are being amortized over their estimated useful life of 5 years, 9 years, 5 years and 4 years, respectively. The straight-line method is being used and is believed to approximate the timeline within which the economic benefit of the underlying intangible asset will be realized.

 

Goodwill of $669,000 was recognized as the excess purchase price over the acquisition-date fair value of net assets acquired. Goodwill is estimated to represent the synergistic values expected to be realized from the combination of the two businesses. The goodwill is expected to be deductible for tax purposes.

 

The pro-forma effect assuming the business combination with BeneYOU discussed above had occurred at the beginning of 2019 is not presented as the information was not available.

 

 

 

Khrysos Global, Inc.

 

On February 12, 2019, the Company and KII entered into an asset and equity purchase agreement (the “AEPA”) with Khrysos Global, and Leigh Dundore and Dwayne Dundore (collectively, the “Khrysos Representing Party”), for KII to acquire substantially all the assets of Khrysos Global and all the outstanding equity of INXL and INXH. The collective business manufactures proprietary systems to provide end-to-end extraction and processing that allow for the conversion of hemp feed stock into hemp oil and hemp extracts.

 

The aggregate consideration payable for the assets of Khrysos Global and the equity of INXL and INXH of $16,000,000 is to be paid as set forth under the terms of the AEPA and allocated between Khrysos Global and Leigh Dundore in such manner as they determine at their discretion.

 

At closing, Khrysos Global and the Khrysos Representing Party received an aggregate of 1,794,972 shares of the Company’s common stock which had a value of $14,000,000 for the purposes of the AEPA and $500,000 in cash. The fair value of the common stock calculated as part of the acquisition valuation was approximately $14,000,000. In addition, the Company agreed to pay the sellers $1,500,000 in cash towards the AEPA of which $1,000,000 was paid to Khrysos Global and the Khrysos Representing Party during 2019. The remaining cash payment of $500,000 was not paid as of the filing date herewith as the Company continues to evaluate the terms of the acquisition agreement in conjunction with the termination of the KII President, noted below. At September 30, 2020 and December 31, 2019, the Company’s remaining liability of $500,000, was outstanding and recorded as accrued expenses on the condensed consolidated balance sheet.

 

The AEPA contains customary representations, warranties and covenants of the Company, Khrysos Global and the Khrysos Representing Party. Subject to certain customary limitations Khrysos Global and the Khrysos Representing Party have agreed to indemnify the Company and KII against certain losses related to, among other things, breaches of the Khrysos Representing Party’s representations and warranties, certain specified liabilities and the failure to perform covenants or obligations under the AEPA.

 

In conjunction with the acquisition and organization of KII, the Company retained Dwayne Dundore as President of KII. Previously agreed-upon equity compensation in the form of warrants that was to be provided as part of the closing to Dwayne Dundore by the Company were mutually terminated. Effective September 17, 2020, Dwayne Dundore was no longer employed with KII or the Company.

 

The Company has estimated fair value at the date of acquisition of the acquired tangible and intangible assets and liabilities as follows (in thousands):

 

Present value of cash consideration

  $ 1,894  

Estimated fair value of common stock issued

    14,000  

Aggregate purchase price

  $ 15,894  

 

The following table summarizes the estimated and as adjusted fair values of the assets acquired and liabilities assumed in February 2019 (in thousands):

 

Current assets

  $ 636  

Inventory

    1,264  

Property, plant and equipment

    1,133  

Trademarks and trade name

    1,876  

Customer-related intangible

    5,629  

Non-compete intangible

    956  

Goodwill

    6,831  

Current liabilities

    (1,904

)

Notes payable

    (527

)

Net assets acquired

  $ 15,894  

 

The reported fair value of intangible assets acquired in the amount of $8,461,000 was determined through the use of a third-party valuation firm using various income and cost approach methodologies. Specifically, the intangibles identified in the acquisition were trademarks and trade name, customer relationships and non-compete agreement. The trademarks and trade name, customer relationships and non-compete agreement are being amortized over their estimated useful life of 8 years, 4 years and 6 years, respectively. The straight-line method is being used and is believed to approximate the timeline within which the economic benefit of the underlying intangible asset will be realized. In connection with the Company’s annual impairment test in 2019, the net book value of intangible assets of $8,461,000 was determined to be impaired. (See Note 5)

 

Goodwill of $6,831,000 was recognized as the excess purchase price over the acquisition-date fair value of net assets acquired. In connection with the Company’s annual impairment test in 2019, the full amount of goodwill recognized was determined to be impaired. (See Note 5)

 

The costs related to the acquisition are included in legal and accounting fees and were expensed as incurred.

 

The pro-forma effect assuming the business combination with KII discussed above had occurred at the beginning of 2019 is not presented as the information was not available. 

 

- 17-

 

 

 

Note 3.  Related Party Transactions

 

Hernandez, Hernandez, Export Y Company and H&H Coffee Group Export Corp.

 

The Company’s wholly-owned subsidiary, CLR, is associated with Hernandez, Hernandez, Export Y Company (“H&H”), a Nicaragua company, through sourcing arrangements to procure Nicaraguan grown green coffee beans. As part of the 2014 Siles acquisition, CLR engaged the owners of H&H, Alain Piedra Hernandez (“Mr. Hernandez”) and Marisol Del Carmen Siles Orozco (“Ms. Orozco”), as employees to manage Siles.

 

H&H is a sourcing agent that purchases raw green coffee beans from the local producers in Nicaragua and supplies CLR’s mill with unprocessed green coffee for processing. CLR does not have a direct relationship with the local producers and is dependent on H&H to negotiate agreements with local producers for the supply and provide to CLR’s mill raw unprocessed green coffee to CLR’s mill in a timely and efficient manner. Substantially all the green coffee processed through the Siles mill was coffee assigned to CLR for processing. During the three and nine months ended September 30, 2019, CLR’s largest customer for green coffee beans was H&H Coffee Group Export Corp. (“H&H Export”), a company related to H&H. In consideration for H&H's sourcing of green coffee for processing within CLR’s mill, CLR and H&H share in the green coffee profit from milling operations.

 

During the three and nine months ended September 30, 2020, CLR had purchases from H&H of approximately $1,072,000 and $2,847,000, respectively, and had purchases from H&H Export of $229,000 and $700,000, respectively. CLR made purchases from H&H of approximately $2,828,000 during the nine months ended September 30, 2019.

 

During the three months ended September 30, 2020 and 2019, CLR recorded net revenues from H&H Export of approximately $211,000 and $29,000, respectively, and $535,000 and $6,416,000, respectively, for the nine months then ended.

 

At September 30, 2020 and December 31, 2019, CLR's accounts receivable balances for customer related revenue from H&H Export were approximately $7,871,000 and $8,707,000 of which the full amounts were past due at the corresponding periods. As a result, the Company reserved $7,871,000 as bad debt related to the accounts receivable balances for both periods, which was net of collections through December 31, 2020.

 

At September 30, 2020, the following balances were recorded from transactions with H&H:

 

 

Prepaid expenses and other current assets of approximately $1,017,000 related to green coffee acquisition,  

 

accounts payable of $230,000 related to billings for freight and other charges by H&H,

 

accrued expenses of $544,000 primarily related to mill operation costs, and

 

accrued expenses offset of $994,000 related to overpaid cost of green coffee.

 

H&H Finance Agreement 

 

In March 2020, CLR entered into a Finance, Security and ARAP Monetization Agreement (the “H&H Finance Agreement”) with H&H Export Y CIA. LTDA and H&H Export (collectively, the “H&H Export Group”). The H&H Finance Agreement was designed to provide the Company with access to a continued supply of unprocessed green coffee beans for the 2020 growing season and a solution for funding of the continued operations of the Company’s green coffee distribution business. Pursuant to the Agreement, the H&H Export Group had agreed to allow a Nicaraguan agency (the “Nicaraguan Agency”) to advance on behalf of the H&H Export Group, approximately $22,000,000 of the $30,100,000 of accounts receivable owed by H&H Export to CLR for its purchase of processed green coffee during the 2019 season. The Nicaraguan Agency also entered into a $46,500,000 credit facility with the H&H Export Group to provide funding for the H&H Export Group’s future coffee purchases of unprocessed green coffee from independent producers. Of the 2020 sales amounts to be billed by CLR for future coffee purchases of processed coffee, CLR was to be paid an additional amount, at a rate of $0.225 per pound of processed green coffee shipped to customers, to be applied to the remaining outstanding 2019 accounts receivable balance owed by H&H Export to CLR. Until such time as the entire accounts receivable balance is paid in full, H&H Export has agreed not take any profit interest. However, given the COVID crisis’ impact on the 2020 growing season and the continued delay in full payment of the 2020 receivable balances, management considered H&H Export accounts receivable impaired at September 30, 2020. Subsequent to the H&H Finance Agreement, CLR adopted the recognition of recording revenues at net for sales between CLR and H&H Export.

 

In March 2021, CLR entered into a master relationship agreement with the owners of H&H in order to memorialize the various agreements and modifications to those agreements. (See Note 13)

 

H&H Export Note Receivable

 

In December 2018, CLR advanced $5,000,000 to H&H Export to provide services in support of a five-year contract for the sale and processing of 41 million pounds of green coffee beans on an annual basis. The services include providing hedging and financing opportunities to producers and delivering harvested coffee to the Company’s mills.  In March 2019, this advance was converted to a $5,000,000 loan agreement as a note receivable and bears interest at 9.00% per annum and is due and payable by H&H Export at the end of each year’s harvest season, but no later than October 31 for any harvest year. In October 2019, CLR and H&H Export amended the March 2019 agreement in terms of the maturity date such that all outstanding principal and interest was due and payable at the end of the 2020 harvest (or when the 2020 season’s harvest was exported and collected), but never to be later than November 30, 2020.

 

Management reviewed the security against the loan and the impact of the underlying COVID crisis and determined that the full amount of the note receivable including interest of approximately $5,677,000 and $5,340,000 was not collected at September 30, 2020 and December 31, 2019, respectively, and therefore the full amounts were recognized as an allowance for collectability at the end of each respective period.

 

 

 

Mill Construction Agreement between CLR and H&H

 

In January 2019, to accommodate CLR’s green coffee purchase contract, CLR entered into a mill construction agreement with H&H and H&H Export, Mr. Hernandez and Ms. Orozco (together with H&H, collectively referred to as the “Nicaraguan Partner”), pursuant to which the Nicaraguan Partner agreed to transfer a 45-acre tract of land in Matagalpa, Nicaragua (the “Matagalpa Property”) to be owned 50% by the Nicaraguan Partner and 50% by CLR. In consideration for the land acquisition the Company issued to H&H Export, 153,846 shares of common stock. The fair value of the shares issued was $1,200,000 and was based on the stock price on the date of issuance of the shares. In addition, the Nicaraguan Partner and CLR agreed to contribute $4,700,000 each toward construction of a processing plant, office, and storage facilities on the Matagalpa Property (collectively the “Matagalpa Mill”) for processing coffee in Nicaragua. The addition of the mill will accommodate CLR’s green coffee contract commitments.

 

For the three and nine months ended September 30, 2020, CLR made payments of approximately $706,000 and $1,506,000, respectively, towards the Matagalpa mill project. For the nine months ended September 30, 2019, CRL made payments toward the Matagalpa mill project of $2,150,000.

 

At September 30, 2020, CLR contributed a total of $4,556,000 towards the construction of the Matagalpa mill project, which is included in construction in process within property and equipment, net on the Company's consolidated balance sheets, and paid a total of $1,304,000 for operating equipment. At September 30, 2020, the Nicaraguan Partner contributed a total of $2,528,000 towards the Matagalpa Mill project. At the filing date of this Quarterly Report on Form 10-Q, the Matagalpa Mill was still incomplete for total operations.

 

In January 2019, the Company issued 295,910 shares of common stock to H&H Export to pay for certain working capital, construction and other payables. In connection with the issuance, the Company over issued 121,649 shares of common stock, resulting in the net issuance of common stock to settle payables of 174,261 shares. H&H Export agreed to reimburse CLR for the over issuance of the 121,649 shares of common stock in cash. At September 30, 2020 and December 31, 2019, the value of the shares was approximately $73,000 and $397,000, respectively, based on the stock price at the respective periods. Management reviewed the amount due in conjunction with the impact of the underlying COVID crisis and has determined that the full receivable balances were more than likely to be uncollected at September 30, 2020 and December 31, 2019, and therefore the full amount was recognized as an allowance for collectability at the respective periods.

 

Amended Operating and Profit-Sharing Agreement between CLR and H&H

 

In January 2019, CLR entered into an amendment to the March 2014 operating and profit-sharing agreement with the owners of H&H. In addition, CLR and H&H, Mr. Hernandez and Ms. Orozco restructured their profit-sharing agreement in regard to profits from green coffee sales and processing that increased CLR’s profit participation by an additional 25%. Under the new terms of the agreement with respect to profit generated from green coffee sales and processed from La Pita or the Matagalpa Mill, now will provide for a split of profits of 75% to CLR and 25% to the Nicaraguan Partner, after certain conditions are met.  Profit-sharing income for the three and nine months ended September 30, 2020 was approximately $424,000 and $635,000, respectively. The profit-sharing expense for the three and nine months ended September 30, 2019 was approximately $863,000 and $1,331,000, respectively.

 

Joint Venture Agreement in Nicaragua for Hemp Processing Center between the CLR and KII and Nicaraguan partner

 

In April and July 2020, CLR and KII (the U.S. Partners) entered into agreements (the “Hemp Joint Venture Agreements”) with H&H Export and Fitracomex, Inc. (“Fitracomex”) (collectively “The Nicaraguan JV Partners”) and established the Nicaraguan Hemp Grow and Extractions Group joint venture (the “Hemp Joint Venture”). Fitracomex is indirectly related the Company due to its relationship with H&H and is being treated as a related party.

 

In accordance with the terms of the Hemp Joint Venture Agreements, H&H Export will contribute the 2,200-acre Chaguitillo Farms in Sebaco-Matagalpa, Nicaragua which will be owned by H&H Export and the U.S. Partners on a 50/50 basis separate from the Hemp Joint Venture should the Hemp Joint Venture determine to sell the land in the future.

 

The Nicaraguan JV Partners will contribute the excavation and preparation for hemp growth of the 2,200 acres, installation of electrical service, and the construction of 45,000 square feet of buildings to be used for office, processing, storage, drying and green house space.

 

 

 

The U.S. Partners will contribute all the necessary extraction equipment to convert hemp to crude oil and will also provide the feminized hemp seeds for the pilot grow program, along with their expertise in the hemp business. The U.S. Partners will also provide all necessary working capital as required.

 

In April 2020, the Company issued 1,500,000 shares of restricted common stock to Fitracomex in accordance with the Hemp Joint Venture Agreements. The fair value of the shares at issuance was approximately $2,490,000. The Company also agreed to issue warrants to Fitracomex for the purchase 5,000,000 shares of the Company’s common stock at an exercise price of $1.50, exercisable for a term of five years after completion of the construction and upon the approval of the Company’s stockholders. At December 31, 2020, the Company reserved the full amount of the investment issued to Fitracomex.

 

The U.S. Partners and H&H Export will serve as the managing partners and all business decisions will require prior consent and agreement of both parties. The net profits and net losses for each fiscal period shall be allocated twenty five percent to the Nicaraguan JV Partners and seventy five percent to the U.S. Partners. At the filing date of this Quarterly Report on Form 10-Q, the Hemp Joint Venture is currently being assessed for changing market conditions related to the hemp industry, and as a result of the fluctuating indicators the Company is considering the timing of entering the market space in regard to the launch of this project.

 

Other Agreements between CLR, H&H and H&H Export

 

In January 2019, H&H Export sold to CLR its espresso brand Café Cachita in consideration of the issuance of 100,000 shares of the Company’s common stock. The shares of common stock issued were valued at $7.50 per share.

 

In May 2017, CLR entered a settlement agreement, as amended, with Mr. Hernandez who was issued a warrant for the purchase of 75,000 shares of the Company’s common stock at a price of $2.00 with an expiration date of three years, in lieu of an obligation due from CLR to H&H as relates to a sourcing and supply agreement with H&H and H&H Export. The warrants were outstanding at December 31, 2019 and expired in May 2020.

 

Other Related Party Transactions 

 

Richard Renton

 

Richard Renton was a member of the board of directors until February 11, 2020 and owned WVNP, Inc., a supplier of certain inventory items sold by the Company.  The Company made purchases from WVNP Inc. of approximately $56,000 during the three months ended March 31, 2020. The Company made purchases from WVNP Inc. of approximately $8,000 and $120,000 for the three and nine months ended September 30, 2019, respectively. In addition, Mr. Renton is a distributor of the Company and was paid distributor commissions of $81,000 for the three months ended March 31, 2020.

 

Carl Grover (Estate of Carl Wilford Grover)

 

Mr. Grover was the sole beneficial owner of in excess of 5% of the Company’s outstanding common shares at September 30, 2020 and December 31, 2019. At September 30, 2020 and December 31, 2019, the balance of the borrowing from the credit agreement the Company entered into with Mr. Grover in December 2018 was approximately $4,763,000 and $4,085,000, respectively, net of debt discounts. (See Note 6)

 

In July 2019, Mr. Grover acquired 600,242 shares of the Company's common stock upon the partial exercise at $4.60 per share of a 2014 warrant to purchase 782,608 shares of common stock held by him. In connection with such exercise, the Company received approximately $2,761,000 from Mr. Grover, issued to Mr. Grover 50,000 shares of restricted common stock as an inducement fee and agreed to extend the expiration date of the July 2014 warrant held by him to December 15, 2020, and the exercise price of the warrant was adjusted to $4.75 with respect to 182,366 shares of common stock remaining for exercise thereunder.

 

Paul Sallwasser

 

Mr. Paul Sallwasser is a member of the board directors, and prior to joining the Company’s board of directors he acquired in the Company’s 2014 private placement a note in the principal amount of $75,000 convertible into 10,714 shares of common stock and a warrant exercisable for 14,673 shares of common stock. Mr. Sallwasser additionally acquired in the Company’s 2017 private placement a note in the principal amount of $38,000 convertible into 8,177 shares of common stock and a warrant issued to purchase 5,719 shares of common stock. Mr. Sallwasser also acquired, as part of the 2017 private placement in exchange for the 2015 note that he acquired in the Company’s 2015 private placement, an additional 2017 note in the principal amount of $5,000 convertible into 1,087 shares of common stock and a 2017 warrant exercisable for 543 shares of common stock.

 

In March 2018, the Company completed its Series B offering and in accordance with the terms of the 2017 notes, Mr. Sallwasser’s 2017 notes converted to 9,264 shares of the Company’s common stock. Mr. Sallwasser’s 2017 warrants of to purchase an aggregate 6,262 shares of common stock expired in July and August 2020.

 

In August 2019, Mr. Sallwasser acquired 14,673 shares of the Company's common stock upon the exercise of his 2014 warrant. In connection with the exercise, Mr. Sallwasser applied approximately $67,000 of the proceeds of his 2014 note due to him from the Company as consideration for the warrant exercise. The warrant exercise proceeds to the Company would have been approximately $67,000. The Company paid the balance owed to him under his 2014 note including accrued interest of approximately $8,000.

 

At September 30, 2020 and 2019, Mr. Sallwasser owned 76,924 shares of common stock and options to purchase an aggregate of 116,655 shares of common stock, which are exercisable.

 

 

 

Daniel Mangless

 

Daniel Mangless became a beneficial owner of in excess of 5% of the Company’s outstanding common stock upon consummation of a securities purchase agreement transaction in March 2020.

 

In February 2019, the Company entered into a securities purchase agreement with Mr. Mangless pursuant to which the Company sold 250,000 shares of common stock at an offering price of $7.00 per share. Pursuant to the purchase agreement, the Company also issued Mr. Mangless a three-year warrant to purchase 250,000 shares of common stock at an exercise price of $7.00. The Company received proceeds of $1,750,000 from the stock offering. (See Note 10)

 

In June 2019, the Company entered into a second securities purchase agreement with Mr. Mangless pursuant to which the Company sold 250,000 shares of common stock at an offering price of $5.50 per share. The Company received proceeds of $1,375,000 from the stock offering. (See Note 10)

 

In March 2020, the Company entered into a securities purchase agreement with Mr. Mangless, pursuant to which the Company issued a senior secured promissory note in the principal amount of $1,000,000 which matured in December 2020. In addition, the Company issued 50,000 shares of common stock in connection with this senior secured promissory note. (See Note 6 and 10)

 

In February 2021, Mr. Mangless liquated some of his Youngevity common stock and is no longer a beneficial owner of in excess of 5% of the outstanding shares of common stock. (See Note 13)

 

In April 2021, the Company entered into a settlement agreement with Mr. Mangless related to the payment schedule of the senior secured promissory note issued in March 2020. In addition, as part of the settlement agreement the Company issued Mr. Mangless 1,000,000 shares of common stock. (See Note 13)

 

2400 Boswell LLC

 

2400 Boswell LLC (“Boswell”) is the owner and lessor of the building occupied by the Company for its corporate office and warehouse in Chula Vista, California. The Company acquired Boswell from an immediate member of the Company’s Chief Executive Officer in 2013. (See Note 6)

 

JJL Equipment Holding, LLC

 

In connection with the acquisition of Khrysos Global, the Company held a deposit from JJL Equipment Holding, LLC (“JJL Equipment”) for an equipment purchase of approximately $230,000 and $233,000 on September 30, 2020 and December 31, 2019, respectively. Leigh Dundore is a member and part owner of JJL Equipment. The deposit is to be applied to future machinery and equipment orders from JJL Equipment and was recorded in other current liabilities in the consolidated balance sheet.

 

Youngevity Be the Change Foundation

 

Youngevity Be the Change Foundation (the “Youngevity Foundation”) was formed in 2013 as a 501 c 3 charitable organization. The Company’s Chief Executive Officer and its President and Chief Investment Officer both serve officers and directors of the Youngevity Foundation, as well as the Company’s Chief Operating Officer and the wife of the Chief Investment Officer who both serve as a director of the Youngevity Foundation. During the three months ended September 30, 2020 and 2019, the Company contributed approximately $22,000 and $24,000, respectively, and $92,000 and $82,000, respectively, for the nine months then ended. At September 30, 2020 and December 31, 2019, the liability representing future contributions to be made to the Youngevity Foundation by the Company was $444,000 and $357,000, respectively, and was included in current liabilities on the Company’s consolidated balance sheets.

 

Daniel Briskie and Maida Briskie

 

Daniel Briskie and Maida Briskie, the father and mother of the Company’s Chief Investment Officer, entered into note purchase agreements in the principal amount of $25,000 in September 2014 related to the Company’s private placement offering in 2014.  In September 2019, the Company entered into an agreement with Daniel Briskie and Maida Briskie to extend the maturity date of their 2014 PIPE Note for one year. At December 31, 2019, the balance of the loan was $25,000 which was paid off in September 2020. (See Note 7).

 

Douglas Briskie

 

Douglas Briskie, the brother of the Company’s Chief Investment Officer, entered into note purchase agreements in the principal amount of $50,000 in August 2014 related to the Company’s private placement offering in 2014. The note was paid in full in August 2019. (See Note 7).

 

 

 

 

Note 4. Revenue Recognition

 

The following table summarizes disaggregated revenue by segment (in thousands):

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2020

   

2019

   

2020

   

2019

 
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  

Direct selling

  $ 31,319     $ 30,256     $ 92,750     $ 95,800  

Processed green coffee

    254       (22

)

    773       1,046  

Milling and processing services

    211       29       535       6,416  

Roasted coffee and other

    2,017       2,933       7,467       9,002  

Commercial coffee

    2,482       2,940       8,775       16,464  

Commercial hemp

    201       184       1,000       525  

Total revenue

  $ 34,002     $ 33,380     $ 102,525     $ 112,789  

 

Contract Balances  

 

As of September 30, 2020 and December 31, 2019, deferred revenues were approximately $10,954,000 and $3,569,000, respectively. Deferred revenues in the direct selling segment related to customer deposits were $1,800,000 and $1,626,000 on September 30, 2020 and December 31, 2019, respectively. Deferred revenues related to the rewards program in the direct selling segment that began at the beginning of 2020 were $2,624,000 at September 30, 2020. Deferred revenues in the direct selling segment related to Heritage Makers were $1,598,000 and $1,795,000 at September 30, 2020, and December 31, 2019, respectively. Deferred revenues related to pre-enrollment in upcoming conventions were $148,000 at December 31, 2019. The Company did not have a deferred revenue balance related to pre-enrollment in upcoming conventions at September 30, 2020. 

 

Deferred revenues in the commercial coffee segment related to customer deposits were $4,305,000 at September 30, 2020. The commercial coffee segment did not have a deferred revenue balance on December 31, 2019.

 

Deferred revenues in the commercial hemp segment related to customer deposits were $627,000 on September 30, 2020. The commercial hemp segment did not have a deferred revenue balance on December 31, 2019.

 

The following table summarizes the classification of deferred revenues balances on the balance sheets (in thousands):

 

   

September 30,

2020

   

December 31,

2019

 
   

(unaudited)

         

Accrued expenses

  $ 627     $ -  

Deferred revenue

    8,527       1,943  

Other current liabilities

    1,800       1,626  

Deferred revenue, total

  $ 10,954     $ 3,569  

 

 

Note 5.  Selected Consolidated Balance Sheet Information

 

Accounts Receivable, net

 

Net accounts receivable consists of the following (in thousands):

 

   

September 30,

2020

   

December 31,

2019

 
   

(unaudited)

         

Accounts receivable

  $ 11,253     $ 11,142  

Allowance for doubtful accounts

    (8,210

)

    (8,240

)

Accounts receivable, net

  $ 3,043     $ 2,902  

 

On September 30, 2020 and December 31, 2019, CLR's accounts receivable balance for customer related revenue by H&H Export was approximately $8,707,000 of which the full amount was past due at the respective periods. As a result, the Company reserved $7,871,000 as bad debt related to the accounts receivable balances for both periods, which was net of collections through December 31, 2020.

 

 

 

Inventory, net

 

Inventories consist of the following (in thousands):

 

   

September 30,

2020

   

December 31,

2019

 
   

(unaudited)

         

Finished goods

  $ 12,448     $ 14,890  

Raw materials

    13,382       11,694  

Total inventory

    25,830       26,584  

Reserve for excess and obsolete

    (3,794

)

    (3,878

)

Inventory, net

  $ 22,036     $ 22,706  

 

Property and Equipment, net

 

Property and equipment consist of the following (in thousands):

 

   

September 30,

2020

   

December 31,

2019

 
   

(unaudited)

         

Buildings

  $ 4,117     $ 4,789  

Leasehold improvements

    3,148       2,948  

Land

    2,544       3,307  

Land improvements

    606       606  

Producing coffee trees

    553       553  

Manufacturing equipment

    10,464       9,568  

Furniture and other equipment

    2,062       2,050  

Computer software

    1,442       1,420  

Computer equipment

    2,714       2,648  

Vehicles

    326       326  

Assets held for sale (1)

    1,496       -